Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
1110001D 15Rik |  |
NM_026763 |
RIKEN cDNA 1110001D15 gene (1110001D15Rik), mRNA [NM_026763] |
KLA | 1.01 |
1.00 |
1.05 |
1.06 |
1.06 |
1.07 |
1.04 |
| ATP | 1.03 |
1.02 |
1.06 |
1.03 |
1.09 |
1.11 |
.95 |
| KLA/ATP | 1.04 |
1.02 |
1.07 |
1.05 |
1.01 |
1.06 |
1.04 |
|
3222402P 14Rik |  |
AK035077 |
12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430084I02 product:SERINE/THREONINE PROTEIN PHOSPHATASE 2A, 72/130 KDA REGULATORY SUBUNIT B (PP2A, SUBUNIT B, B-PR72/PR130) |
KLA | 1.06 |
.96 |
1.06 |
.93 |
.97 |
.96 |
.93 |
| ATP | .98 |
1.04 |
.93 |
.98 |
.95 |
1.10 |
.93 |
| KLA/ATP | 1.00 |
1.06 |
.91 |
.92 |
.99 |
.94 |
.95 |
|
3222402P 14Rik |  |
XM_001475836 |
gb|PREDICTED: Mus musculus RIKEN cDNA 3222402P14 gene (3222402P14Rik), mRNA [XM_001475836] |
KLA | 1.38 |
1.32 |
1.26 |
1.05 |
.84 |
.83 |
.85 |
| ATP | 1.01 |
1.02 |
.93 |
.94 |
1.00 |
1.04 |
.87 |
| KLA/ATP | 1.37 |
1.47 |
1.01 |
.91 |
.86 |
.87 |
.75 |
|
4932417H 02Rik |  |
AK029341 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4832440O09 product:Hypothetical ARM repeat structure containing protein, full insert sequence. [AK029341] |
KLA | .90 |
.86 |
.81 |
.84 |
.93 |
.84 |
.93 |
| ATP | 1.00 |
1.06 |
1.02 |
.88 |
.93 |
.76 |
1.06 |
| KLA/ATP | .90 |
.86 |
.88 |
.79 |
.83 |
.80 |
.98 |
|
4932417H 02Rik |  |
NM_028898 |
RIKEN cDNA 4932417H02 gene (4932417H02Rik), mRNA [NM_028898] |
KLA | .76 |
.72 |
.83 |
.63 |
.61 |
.68 |
.75 |
| ATP | .99 |
.95 |
.79 |
.76 |
.66 |
.62 |
1.47 |
| KLA/ATP | .78 |
.71 |
.56 |
.50 |
.39 |
.48 |
.89 |
|
AK044510
|  |
AK044510 |
adult retina cDNA, RIKEN full-length enriched library, clone:A930017M14 product:laminin, alpha 1, full insert sequence. [AK044510] |
KLA | .96 |
1.07 |
1.03 |
1.05 |
1.00 |
1.06 |
1.16 |
| ATP | 1.04 |
1.04 |
1.04 |
1.04 |
1.05 |
1.08 |
1.01 |
| KLA/ATP | .96 |
1.08 |
1.07 |
1.10 |
1.12 |
1.08 |
1.01 |
|
AK045366
|  |
AK045366 |
adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230107A03 product:unclassifiable, full insert sequence [AK045366] |
KLA | .88 |
.80 |
.79 |
.86 |
.89 |
.97 |
1.07 |
| ATP | 1.21 |
1.67 |
2.40 |
3.50 |
2.58 |
1.29 |
1.12 |
| KLA/ATP | .97 |
.98 |
1.30 |
1.76 |
1.26 |
1.15 |
1.06 |
|
AK077928
|  |
AK077928 |
13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030447G09 product:unclassifiable, full insert sequence. [AK077928] |
KLA | .94 |
.91 |
.95 |
.95 |
1.04 |
.95 |
.99 |
| ATP | 1.11 |
1.05 |
.97 |
.87 |
.98 |
.86 |
.91 |
| KLA/ATP | 1.01 |
1.05 |
.97 |
.89 |
.92 |
.92 |
.93 |
|
Akt1 |  |
NM_009652 |
thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] |
KLA | .80 |
.80 |
.75 |
.75 |
.71 |
.70 |
.82 |
| ATP | 1.00 |
1.02 |
.76 |
.85 |
.76 |
.68 |
.84 |
| KLA/ATP | .82 |
.80 |
.64 |
.68 |
.67 |
.61 |
.72 |
|
Akt2 |  |
NM_007434 |
thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] |
KLA | 1.45 |
1.49 |
1.81 |
1.61 |
1.83 |
1.17 |
.92 |
| ATP | 1.12 |
1.12 |
1.00 |
1.28 |
1.20 |
.94 |
1.06 |
| KLA/ATP | 1.48 |
1.70 |
1.69 |
1.58 |
1.57 |
1.32 |
1.27 |
|
Akt3 |  |
NM_011785 |
thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] |
KLA | 3.42 |
3.45 |
5.31 |
5.16 |
4.65 |
3.80 |
2.12 |
| ATP | 1.12 |
1.22 |
1.10 |
1.37 |
1.02 |
1.11 |
1.56 |
| KLA/ATP | 3.72 |
4.17 |
4.62 |
4.64 |
2.74 |
2.05 |
3.82 |
|
Angpt1 |  |
NM_009640 |
angiopoietin 1 (Angpt1), mRNA [NM_009640] |
KLA | 1.19 |
1.24 |
1.37 |
1.49 |
1.45 |
1.20 |
.99 |
| ATP | 1.02 |
1.05 |
1.03 |
1.05 |
1.04 |
1.01 |
1.06 |
| KLA/ATP | 1.21 |
1.23 |
1.33 |
1.36 |
1.30 |
1.21 |
1.07 |
|
Angpt2 |  |
NM_007426 |
angiopoietin 2 (Angpt2), mRNA [NM_007426] |
KLA | .22 |
.22 |
.18 |
.22 |
.31 |
1.11 |
2.43 |
| ATP | .93 |
.92 |
1.36 |
3.33 |
5.55 |
1.44 |
7.53 |
| KLA/ATP | .20 |
.20 |
.28 |
.54 |
1.94 |
2.41 |
6.55 |
|
Angpt4 |  |
NM_009641 |
angiopoietin 4 (Angpt4), mRNA [NM_009641] |
KLA | 1.01 |
.99 |
1.00 |
1.09 |
.96 |
.96 |
.88 |
| ATP | .98 |
.97 |
1.02 |
.95 |
1.02 |
1.01 |
.93 |
| KLA/ATP | .97 |
1.01 |
1.02 |
.96 |
.97 |
.93 |
.99 |
|
Atf2 |  |
AK047405 |
10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930056P03 product:activating transcription factor 2, full insert sequence. [AK047405] |
KLA | 1.01 |
1.00 |
1.02 |
1.04 |
1.03 |
1.03 |
1.00 |
| ATP | .99 |
1.00 |
.95 |
1.01 |
1.04 |
.98 |
1.03 |
| KLA/ATP | 1.07 |
1.00 |
.98 |
.99 |
1.00 |
1.03 |
.93 |
|
Atf2 |  |
NM_001025093 |
activating transcription factor 2 (Atf2), transcript variant 1, mRNA [NM_001025093] |
KLA | 1.35 |
1.30 |
1.32 |
1.31 |
1.37 |
1.09 |
1.20 |
| ATP | 1.15 |
1.17 |
.99 |
1.11 |
1.22 |
1.39 |
1.28 |
| KLA/ATP | 1.38 |
1.42 |
1.21 |
1.28 |
1.17 |
1.33 |
1.69 |
|
Atf4 |  |
NM_009716 |
activating transcription factor 4 (Atf4), mRNA [NM_009716] |
KLA | .91 |
1.06 |
1.13 |
1.31 |
1.92 |
2.59 |
3.01 |
| ATP | 1.05 |
1.14 |
1.34 |
2.88 |
4.84 |
2.36 |
2.56 |
| KLA/ATP | 1.14 |
1.08 |
1.17 |
2.40 |
3.72 |
3.54 |
3.62 |
|
BB217526
|  |
AK083592 |
9 days embryo whole body cDNA, RIKEN full-length enriched library, clone:D030051F04 product:unclassifiable, full insert sequence [AK083592] |
KLA | 1.53 |
1.19 |
1.21 |
1.15 |
1.61 |
1.14 |
.87 |
| ATP | 1.33 |
1.11 |
1.15 |
1.11 |
2.06 |
1.48 |
1.13 |
| KLA/ATP | 1.36 |
1.18 |
1.61 |
1.37 |
1.77 |
1.10 |
1.13 |
|
BC010335
|  |
BC010335 |
fibronectin 1, mRNA (cDNA clone IMAGE:3156499), **** WARNING: chimeric clone ****. [BC010335] |
KLA | .94 |
.88 |
1.01 |
.99 |
.95 |
.95 |
1.07 |
| ATP | 1.06 |
.98 |
1.20 |
1.30 |
1.07 |
.97 |
.97 |
| KLA/ATP | .93 |
1.00 |
1.07 |
1.20 |
1.02 |
.96 |
.94 |
|
Bad |  |
AK029400 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833429M11 product:Bcl-associated death promoter, full insert sequence. [AK029400] |
KLA | 1.15 |
1.22 |
1.26 |
1.31 |
1.40 |
1.67 |
1.59 |
| ATP | .95 |
1.06 |
1.12 |
1.06 |
.78 |
.89 |
1.27 |
| KLA/ATP | 1.25 |
1.39 |
1.33 |
1.29 |
1.11 |
.91 |
1.38 |
|
Bcl2 |  |
NM_009741 |
B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 1, mRNA [NM_009741] |
KLA | .30 |
.26 |
.25 |
.25 |
.34 |
.38 |
.26 |
| ATP | .97 |
.89 |
1.50 |
1.04 |
.99 |
.29 |
.52 |
| KLA/ATP | .28 |
.26 |
.40 |
.33 |
.62 |
.29 |
.12 |
|
Bcl2 |  |
NM_177410 |
B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 2, mRNA [NM_177410] |
KLA | .33 |
.33 |
.37 |
.42 |
.49 |
.46 |
.39 |
| ATP | 1.07 |
1.12 |
1.22 |
1.56 |
1.00 |
.38 |
.76 |
| KLA/ATP | .35 |
.34 |
.54 |
.89 |
.76 |
.36 |
.23 |
|
Bcl2l1 |  |
NM_009743 |
Bcl2-like 1 (Bcl2l1), nuclear gene encoding mitochondrial protein, mRNA [NM_009743] |
KLA | .99 |
1.02 |
1.10 |
1.16 |
1.27 |
.97 |
1.05 |
| ATP | 1.18 |
1.42 |
.81 |
1.26 |
1.51 |
.71 |
1.67 |
| KLA/ATP | 1.21 |
1.30 |
.66 |
1.15 |
1.31 |
1.17 |
1.59 |
|
Bcl2l11 |  |
NM_207680 |
BCL2-like 11 (apoptosis facilitator) (Bcl2l11), transcript variant 1, mRNA [NM_207680] |
KLA | 4.91 |
4.68 |
3.46 |
2.88 |
1.79 |
1.77 |
1.59 |
| ATP | 1.01 |
.98 |
1.30 |
5.07 |
4.70 |
5.53 |
5.58 |
| KLA/ATP | 4.37 |
4.96 |
3.92 |
6.27 |
5.05 |
5.10 |
16.45 |
|
Brca1 |  |
NM_009764 |
breast cancer 1 (Brca1), mRNA [NM_009764] |
KLA | .40 |
.41 |
.40 |
.41 |
.38 |
.50 |
.40 |
| ATP | 1.13 |
1.18 |
1.07 |
.94 |
.76 |
.45 |
.44 |
| KLA/ATP | .42 |
.38 |
.41 |
.47 |
.50 |
.68 |
.46 |
|
Casp9 |  |
NM_015733 |
caspase 9 (Casp9), mRNA [NM_015733] |
KLA | .31 |
.31 |
.40 |
.66 |
.89 |
1.19 |
.91 |
| ATP | .88 |
.77 |
.91 |
.59 |
.43 |
.75 |
.93 |
| KLA/ATP | .26 |
.26 |
.30 |
.28 |
.80 |
1.06 |
.97 |
|
Ccnd1 |  |
S78355 |
gb|Cyl-1=cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. [S78355] |
KLA | .24 |
.23 |
.23 |
.24 |
.29 |
.47 |
.17 |
| ATP | 1.02 |
1.02 |
.88 |
.80 |
.52 |
.10 |
.21 |
| KLA/ATP | .27 |
.23 |
.22 |
.24 |
.27 |
.25 |
.14 |
|
Ccnd2 |  |
NM_009829 |
cyclin D2 (Ccnd2), mRNA [NM_009829] |
KLA | 12.92 |
13.66 |
11.94 |
12.37 |
11.11 |
5.44 |
1.53 |
| ATP | .98 |
.75 |
.50 |
.57 |
1.24 |
2.83 |
.40 |
| KLA/ATP | 11.19 |
11.62 |
10.34 |
7.96 |
7.92 |
7.10 |
2.57 |
|
Ccnd3 |  |
NM_007632 |
cyclin D3 (Ccnd3), transcript variant 1, mRNA [NM_007632] |
KLA | .60 |
.65 |
.86 |
1.02 |
1.91 |
2.26 |
1.45 |
| ATP | 1.05 |
1.14 |
.89 |
1.20 |
.74 |
.76 |
.99 |
| KLA/ATP | .70 |
.67 |
.54 |
.83 |
.61 |
1.19 |
1.45 |
|
Ccne1 |  |
NM_007633 |
cyclin E1 (Ccne1), mRNA [NM_007633] |
KLA | 1.13 |
1.14 |
1.13 |
.78 |
.51 |
.69 |
.55 |
| ATP | .92 |
.94 |
1.09 |
.93 |
.75 |
.71 |
.47 |
| KLA/ATP | 1.13 |
1.17 |
1.45 |
1.24 |
1.33 |
1.50 |
.85 |
|
Ccne2 |  |
NM_001037134 |
cyclin E2 (Ccne2), transcript variant 1, mRNA [NM_001037134] |
KLA | .34 |
.35 |
.42 |
.36 |
.35 |
.36 |
.26 |
| ATP | 1.02 |
1.11 |
1.01 |
.82 |
.58 |
.38 |
.23 |
| KLA/ATP | .36 |
.34 |
.44 |
.43 |
.41 |
.40 |
.25 |
|
Cd19 |  |
NM_009844 |
CD19 antigen (Cd19), mRNA [NM_009844] |
KLA | 1.05 |
1.04 |
1.09 |
1.05 |
1.03 |
1.07 |
1.10 |
| ATP | 1.04 |
1.03 |
.99 |
1.07 |
.93 |
.97 |
.97 |
| KLA/ATP | 1.04 |
1.03 |
1.02 |
.97 |
1.01 |
1.00 |
1.08 |
|
Cdc37 |  |
NM_016742 |
cell division cycle 37 homolog (S. cerevisiae) (Cdc37), mRNA [NM_016742] |
KLA | 1.40 |
1.41 |
1.33 |
1.28 |
1.31 |
1.12 |
.92 |
| ATP | 1.02 |
1.12 |
1.05 |
1.34 |
1.07 |
.66 |
.76 |
| KLA/ATP | 1.42 |
1.45 |
1.40 |
1.72 |
1.35 |
1.01 |
.66 |
|
Cdk2 |  |
NM_016756 |
cyclin-dependent kinase 2 (Cdk2), transcript variant 2, mRNA [NM_016756] |
KLA | .68 |
.67 |
.62 |
.63 |
.60 |
.74 |
.73 |
| ATP | 1.02 |
1.14 |
.91 |
.92 |
.68 |
.71 |
.65 |
| KLA/ATP | .67 |
.64 |
.64 |
.64 |
.61 |
.74 |
.62 |
|
Cdk4 |  |
NM_009870 |
cyclin-dependent kinase 4 (Cdk4), mRNA [NM_009870] |
KLA | .66 |
.72 |
.65 |
.55 |
.46 |
.50 |
.71 |
| ATP | 1.03 |
1.02 |
.53 |
.65 |
.66 |
.63 |
.75 |
| KLA/ATP | .78 |
.61 |
.31 |
.42 |
.44 |
.62 |
.43 |
|
Cdk6 |  |
AK030810 |
adult male thymus cDNA, RIKEN full-length enriched library, clone:5830411I20 product:unclassifiable, full insert sequence [AK030810] |
KLA | 1.05 |
.96 |
.67 |
.51 |
.48 |
.49 |
.45 |
| ATP | 1.02 |
.91 |
.78 |
.49 |
.50 |
.47 |
.44 |
| KLA/ATP | 1.01 |
.89 |
.65 |
.40 |
.36 |
.26 |
.49 |
|
Cdk6 |  |
NM_009873 |
cyclin-dependent kinase 6 (Cdk6), mRNA [NM_009873] |
KLA | 2.63 |
2.36 |
2.14 |
1.80 |
1.55 |
1.32 |
1.03 |
| ATP | 1.11 |
1.21 |
1.06 |
1.23 |
.94 |
1.30 |
2.08 |
| KLA/ATP | 2.58 |
2.69 |
2.24 |
2.25 |
1.38 |
.85 |
3.00 |
|
Cdkn1a |  |
NM_007669 |
cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), transcript variant 1, mRNA [NM_007669] |
KLA | 4.72 |
4.90 |
4.96 |
3.73 |
2.11 |
1.14 |
1.02 |
| ATP | 1.14 |
1.52 |
.95 |
1.69 |
1.47 |
2.21 |
.50 |
| KLA/ATP | 5.99 |
7.08 |
3.86 |
6.37 |
3.00 |
2.55 |
2.05 |
|
Cdkn1b |  |
NM_009875 |
cyclin-dependent kinase inhibitor 1B (Cdkn1b), mRNA [NM_009875] |
KLA | .81 |
.84 |
.84 |
.91 |
.93 |
.88 |
.97 |
| ATP | .99 |
1.09 |
.97 |
1.06 |
1.48 |
.94 |
.91 |
| KLA/ATP | .83 |
.91 |
1.04 |
1.36 |
1.48 |
1.06 |
1.09 |
|
Chad |  |
NM_007689 |
chondroadherin (Chad), mRNA [NM_007689] |
KLA | 1.34 |
1.32 |
1.36 |
1.26 |
1.27 |
1.30 |
1.31 |
| ATP | 1.03 |
.94 |
1.16 |
1.08 |
1.12 |
1.37 |
1.26 |
| KLA/ATP | 1.36 |
1.44 |
1.52 |
1.57 |
1.32 |
1.42 |
1.56 |
|
Chrm1 |  |
NM_001112697 |
cholinergic receptor, muscarinic 1, CNS (Chrm1), transcript variant 1, mRNA [NM_001112697] |
KLA | 1.12 |
.99 |
.97 |
1.09 |
.92 |
.91 |
.97 |
| ATP | .95 |
1.06 |
1.01 |
1.06 |
1.05 |
1.06 |
.99 |
| KLA/ATP | 1.00 |
.99 |
1.02 |
1.00 |
1.05 |
.95 |
1.01 |
|
Chrm2 |  |
NM_203491 |
cholinergic receptor, muscarinic 2, cardiac (Chrm2), mRNA [NM_203491] |
KLA | 1.03 |
1.05 |
.98 |
1.02 |
1.04 |
1.06 |
1.05 |
| ATP | 1.09 |
.94 |
1.08 |
1.06 |
.98 |
1.04 |
.97 |
| KLA/ATP | 1.01 |
1.05 |
.97 |
1.01 |
.98 |
1.07 |
.99 |
|
Chuk |  |
NM_007700 |
conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] |
KLA | 1.32 |
1.42 |
1.41 |
1.17 |
1.32 |
1.22 |
1.40 |
| ATP | 1.22 |
1.30 |
1.18 |
.97 |
1.02 |
1.00 |
1.37 |
| KLA/ATP | 1.56 |
1.61 |
1.21 |
1.09 |
.83 |
.84 |
1.17 |
|
Col11a1 |  |
AK021265 |
12 days embryo spinal cord cDNA, RIKEN full-length enriched library, clone:C530001D20 product:unclassifiable, full insert sequence. [AK021265] |
KLA | 1.02 |
1.01 |
1.03 |
1.06 |
1.02 |
1.03 |
1.05 |
| ATP | .97 |
.92 |
1.02 |
.96 |
.93 |
1.11 |
1.00 |
| KLA/ATP | 1.01 |
.96 |
.97 |
1.00 |
1.04 |
.89 |
1.08 |
|
Col11a1 |  |
NM_007729 |
collagen, type XI, alpha 1 (Col11a1), mRNA [NM_007729] |
KLA | 1.06 |
1.06 |
1.10 |
1.05 |
1.07 |
1.01 |
1.09 |
| ATP | .97 |
.93 |
.95 |
1.03 |
.96 |
1.01 |
1.05 |
| KLA/ATP | 1.03 |
.98 |
1.02 |
1.02 |
.97 |
.99 |
1.05 |
|
Col11a2 |  |
NM_009926 |
collagen, type XI, alpha 2 (Col11a2), mRNA [NM_009926] |
KLA | 5.62 |
5.61 |
5.24 |
4.99 |
3.69 |
1.95 |
1.14 |
| ATP | .95 |
.95 |
1.17 |
1.59 |
1.73 |
1.28 |
1.12 |
| KLA/ATP | 5.25 |
5.62 |
6.37 |
5.73 |
4.79 |
2.22 |
1.39 |
|
Col1a1 |  |
NM_007742 |
collagen, type I, alpha 1 (Col1a1), mRNA [NM_007742] |
KLA | 1.13 |
1.10 |
1.22 |
1.18 |
1.04 |
1.15 |
1.09 |
| ATP | 1.03 |
1.00 |
1.34 |
1.48 |
1.11 |
1.13 |
1.11 |
| KLA/ATP | 1.13 |
1.29 |
1.47 |
1.77 |
1.38 |
1.33 |
1.13 |
|
Col1a2 |  |
AK031577 |
13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030456A07 product:procollagen, type I, alpha 2, full insert sequence. [AK031577] |
KLA | .98 |
1.03 |
1.02 |
1.01 |
1.03 |
1.01 |
.90 |
| ATP | .97 |
.96 |
.96 |
1.00 |
.92 |
1.00 |
1.00 |
| KLA/ATP | .97 |
1.00 |
1.02 |
1.06 |
.96 |
.98 |
1.00 |
|
Col1a2 |  |
NM_007743 |
collagen, type I, alpha 2 (Col1a2), mRNA [NM_007743] |
KLA | 1.25 |
1.20 |
1.58 |
1.41 |
1.32 |
1.51 |
1.08 |
| ATP | .92 |
.97 |
1.50 |
1.66 |
1.38 |
1.23 |
1.14 |
| KLA/ATP | 1.35 |
1.46 |
2.19 |
2.47 |
1.99 |
1.64 |
1.36 |
|
Col24a1 |  |
NM_027770 |
collagen, type XXIV, alpha 1 (Col24a1), mRNA [NM_027770] |
KLA | .96 |
1.03 |
.95 |
.99 |
1.01 |
1.02 |
.98 |
| ATP | .98 |
1.03 |
1.04 |
1.04 |
.95 |
.99 |
1.00 |
| KLA/ATP | 1.04 |
.98 |
1.01 |
.99 |
1.01 |
.93 |
.96 |
|
Col27a1 |  |
AK076297 |
0 day neonate skin cDNA, RIKEN full-length enriched library, clone:4632427K15 product:procollagen, type XXVII, alpha 1, full insert sequence. [AK076297] |
KLA | 1.19 |
1.39 |
1.10 |
1.06 |
1.01 |
1.04 |
.96 |
| ATP | 1.00 |
.99 |
1.02 |
.99 |
1.01 |
1.06 |
1.08 |
| KLA/ATP | 1.23 |
1.26 |
1.12 |
1.10 |
1.12 |
.95 |
1.03 |
|
Col27a1 |  |
NM_025685 |
collagen, type XXVII, alpha 1 (Col27a1), mRNA [NM_025685] |
KLA | 3.10 |
3.05 |
2.89 |
1.86 |
1.37 |
1.14 |
1.16 |
| ATP | 1.02 |
1.00 |
1.10 |
1.22 |
1.24 |
1.15 |
1.12 |
| KLA/ATP | 3.43 |
3.57 |
2.62 |
1.99 |
1.42 |
1.23 |
1.24 |
|
Col2a1 |  |
AK053784 |
0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130308G17 product:unclassifiable, full insert sequence. [AK053784] |
KLA | .95 |
.97 |
1.05 |
.93 |
.94 |
.94 |
.98 |
| ATP | .99 |
.91 |
.97 |
.87 |
.99 |
1.03 |
.93 |
| KLA/ATP | .95 |
1.05 |
.95 |
1.01 |
.97 |
.97 |
1.00 |
|
Col2a1 |  |
NM_031163 |
collagen, type II, alpha 1 (Col2a1), transcript variant 1, mRNA [NM_031163] |
KLA | 1.20 |
1.28 |
1.29 |
1.21 |
1.33 |
1.24 |
1.21 |
| ATP | .98 |
1.02 |
1.02 |
1.09 |
1.02 |
1.01 |
1.09 |
| KLA/ATP | 1.33 |
1.28 |
1.09 |
1.32 |
1.15 |
1.12 |
1.17 |
|
Col3a1 |  |
AK031544 |
13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030449K06 product:PROCOLLAGEN, TYPE III, ALPHA 1 (FRAGMENT) homolog [Mus musculus], full insert sequence. [AK031544] |
KLA | 1.04 |
.95 |
1.01 |
1.04 |
1.04 |
1.03 |
.97 |
| ATP | 1.00 |
.98 |
1.02 |
1.00 |
1.03 |
1.00 |
.98 |
| KLA/ATP | 1.11 |
1.03 |
1.05 |
.90 |
.95 |
1.01 |
.97 |
|
Col3a1 |  |
NM_009930 |
collagen, type III, alpha 1 (Col3a1), mRNA [NM_009930] |
KLA | 1.06 |
1.08 |
1.02 |
.99 |
1.02 |
1.03 |
.99 |
| ATP | .97 |
1.01 |
1.07 |
1.01 |
.92 |
.94 |
.99 |
| KLA/ATP | .97 |
.99 |
1.09 |
1.11 |
.98 |
1.00 |
1.02 |
|
Col4a1 |  |
NM_009931 |
collagen, type IV, alpha 1 (Col4a1), mRNA [NM_009931] |
KLA | 1.13 |
1.19 |
1.12 |
1.09 |
1.04 |
.89 |
.90 |
| ATP | 1.01 |
1.17 |
1.02 |
1.04 |
.91 |
.89 |
.97 |
| KLA/ATP | 1.14 |
1.24 |
1.03 |
1.15 |
.95 |
.86 |
1.01 |
|
Col4a2 |  |
NM_009932 |
collagen, type IV, alpha 2 (Col4a2), mRNA [NM_009932] |
KLA | 1.30 |
1.45 |
1.54 |
1.40 |
1.71 |
1.71 |
2.12 |
| ATP | 1.09 |
1.07 |
.98 |
1.03 |
.92 |
1.21 |
1.42 |
| KLA/ATP | 1.45 |
1.53 |
1.24 |
1.29 |
1.16 |
1.57 |
3.31 |
|
Col4a3 |  |
NM_007734 |
collagen, type IV, alpha 3 (Col4a3), mRNA [NM_007734] |
KLA | 1.09 |
1.11 |
1.12 |
1.10 |
1.05 |
1.06 |
1.04 |
| ATP | 1.02 |
1.03 |
1.01 |
.99 |
1.01 |
1.07 |
1.07 |
| KLA/ATP | 1.04 |
1.13 |
1.01 |
1.09 |
1.02 |
.98 |
1.01 |
|
Col4a4 |  |
NM_007735 |
collagen, type IV, alpha 4 (Col4a4), mRNA [NM_007735] |
KLA | 1.35 |
1.29 |
1.33 |
1.39 |
1.30 |
1.18 |
.98 |
| ATP | 1.14 |
1.08 |
1.30 |
1.54 |
1.54 |
1.34 |
.93 |
| KLA/ATP | 1.37 |
1.41 |
1.70 |
1.88 |
1.67 |
1.29 |
1.19 |
|
Col4a5 |  |
NM_007736 |
collagen, type IV, alpha 5 (Col4a5), mRNA [NM_007736] |
KLA | 1.00 |
.95 |
.95 |
.82 |
.72 |
.58 |
.70 |
| ATP | 1.05 |
1.18 |
.98 |
.88 |
.56 |
.53 |
.57 |
| KLA/ATP | 1.04 |
1.05 |
.83 |
.82 |
.58 |
.49 |
.61 |
|
Col4a6 |  |
NM_053185 |
collagen, type IV, alpha 6 (Col4a6), mRNA [NM_053185] |
KLA | 1.06 |
1.04 |
1.00 |
1.07 |
.94 |
.93 |
.94 |
| ATP | .97 |
.96 |
1.18 |
1.10 |
1.07 |
1.04 |
.86 |
| KLA/ATP | 1.00 |
1.05 |
1.22 |
1.06 |
1.12 |
1.02 |
.93 |
|
Col5a1 |  |
NM_015734 |
collagen, type V, alpha 1 (Col5a1), mRNA [NM_015734] |
KLA | 1.00 |
.99 |
1.07 |
1.01 |
1.03 |
1.01 |
1.10 |
| ATP | 1.02 |
.98 |
1.02 |
1.07 |
.96 |
1.01 |
1.09 |
| KLA/ATP | 1.03 |
1.01 |
1.08 |
1.08 |
1.01 |
1.09 |
1.08 |
|
Col5a2 |  |
NM_007737 |
collagen, type V, alpha 2 (Col5a2), mRNA [NM_007737] |
KLA | .96 |
1.01 |
1.12 |
1.03 |
.99 |
.98 |
.90 |
| ATP | .99 |
1.06 |
1.05 |
1.10 |
.90 |
.98 |
1.06 |
| KLA/ATP | .95 |
1.01 |
1.05 |
1.11 |
1.07 |
1.04 |
1.14 |
|
Col5a3 |  |
NM_016919 |
collagen, type V, alpha 3 (Col5a3), mRNA [NM_016919] |
KLA | 1.33 |
1.48 |
1.48 |
1.47 |
1.45 |
1.31 |
1.08 |
| ATP | 1.06 |
1.02 |
1.08 |
1.06 |
1.07 |
1.35 |
1.48 |
| KLA/ATP | 1.42 |
1.50 |
1.42 |
1.45 |
1.27 |
1.32 |
1.37 |
|
Col6a1 |  |
NM_009933 |
collagen, type VI, alpha 1 (Col6a1), mRNA [NM_009933] |
KLA | 1.08 |
1.12 |
1.29 |
1.16 |
1.17 |
.96 |
1.03 |
| ATP | 1.05 |
1.03 |
1.01 |
1.07 |
.98 |
.96 |
.88 |
| KLA/ATP | 1.16 |
1.18 |
.92 |
1.17 |
1.01 |
.98 |
.92 |
|
Col6a2 |  |
AK044870 |
9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130009B12 product:procollagen, type VI, alpha 2, full insert sequence. [AK044870] |
KLA | 1.06 |
1.00 |
.99 |
.96 |
.96 |
1.00 |
1.01 |
| ATP | .95 |
.95 |
.92 |
1.10 |
1.09 |
1.03 |
1.01 |
| KLA/ATP | 1.01 |
.97 |
.98 |
1.04 |
.98 |
1.04 |
.96 |
|
Col6a2 |  |
NM_146007 |
collagen, type VI, alpha 2 (Col6a2), mRNA [NM_146007] |
KLA | .94 |
1.06 |
1.00 |
1.07 |
1.05 |
1.04 |
1.00 |
| ATP | 1.01 |
.99 |
1.02 |
1.01 |
1.00 |
1.01 |
.98 |
| KLA/ATP | 1.01 |
.99 |
1.04 |
1.01 |
1.08 |
1.01 |
.95 |
|
Col6a3 |  |
AF034136 |
collagen alpha3(VI) (Col6a3) mRNA, partial cds [AF034136] |
KLA | .97 |
1.00 |
1.03 |
1.00 |
1.03 |
1.04 |
1.06 |
| ATP | 1.00 |
.93 |
1.00 |
1.01 |
1.07 |
.97 |
1.01 |
| KLA/ATP | 1.08 |
1.04 |
1.05 |
1.04 |
.99 |
1.10 |
1.02 |
|
Comp |  |
NM_016685 |
cartilage oligomeric matrix protein (Comp), mRNA [NM_016685] |
KLA | 1.02 |
1.09 |
1.18 |
1.08 |
.96 |
1.12 |
.97 |
| ATP | .89 |
1.02 |
.97 |
.95 |
1.13 |
2.59 |
1.24 |
| KLA/ATP | 1.09 |
1.09 |
1.03 |
.98 |
1.60 |
2.02 |
1.15 |
|
Creb1 |  |
NM_009952 |
cAMP responsive element binding protein 1 (Creb1), transcript variant B, mRNA [NM_009952] |
KLA | 1.42 |
1.33 |
1.16 |
.99 |
.83 |
.97 |
.92 |
| ATP | .92 |
.91 |
1.18 |
1.38 |
1.51 |
1.02 |
.75 |
| KLA/ATP | 1.34 |
1.31 |
1.49 |
1.37 |
1.71 |
1.05 |
.93 |
|
Creb3 |  |
NM_013497 |
cAMP responsive element binding protein 3 (Creb3), mRNA [NM_013497] |
KLA | 1.21 |
1.21 |
1.23 |
1.53 |
1.77 |
1.77 |
1.31 |
| ATP | 1.02 |
1.03 |
.99 |
1.05 |
.82 |
.83 |
1.48 |
| KLA/ATP | 1.15 |
1.18 |
1.20 |
1.26 |
1.13 |
1.15 |
1.86 |
|
Creb3l1 |  |
NM_011957 |
cAMP responsive element binding protein 3-like 1 (Creb3l1), mRNA [NM_011957] |
KLA | 1.18 |
1.17 |
1.53 |
1.28 |
1.22 |
1.11 |
1.23 |
| ATP | 1.01 |
1.09 |
.98 |
1.17 |
1.22 |
1.01 |
1.15 |
| KLA/ATP | 1.22 |
1.29 |
1.08 |
1.34 |
1.14 |
1.36 |
1.12 |
|
Creb3l2 |  |
AK082964 |
12 days embryo spinal cord cDNA, RIKEN full-length enriched library, clone:C530025K05 product:unclassifiable, full insert sequence [AK082964] |
KLA | .44 |
.38 |
.37 |
.40 |
.45 |
.42 |
.47 |
| ATP | .90 |
.78 |
1.22 |
.79 |
.54 |
.46 |
.44 |
| KLA/ATP | .41 |
.41 |
.49 |
.43 |
.50 |
.51 |
.23 |
|
Creb3l2 |  |
NM_178661 |
cAMP responsive element binding protein 3-like 2 (Creb3l2), mRNA [NM_178661] |
KLA | .98 |
.87 |
.76 |
.98 |
1.03 |
.87 |
1.12 |
| ATP | 1.20 |
1.18 |
1.50 |
1.35 |
.86 |
1.32 |
1.50 |
| KLA/ATP | .98 |
1.04 |
1.15 |
1.05 |
.79 |
1.27 |
1.25 |
|
Creb3l3 |  |
NM_145365 |
cAMP responsive element binding protein 3-like 3 (Creb3l3), mRNA [NM_145365] |
KLA | .66 |
.75 |
.65 |
.85 |
1.04 |
1.44 |
1.73 |
| ATP | 1.02 |
.98 |
.97 |
1.09 |
.85 |
.69 |
1.11 |
| KLA/ATP | .70 |
.66 |
.71 |
.83 |
.80 |
.85 |
1.05 |
|
Creb3l4 |  |
NM_030080 |
cAMP responsive element binding protein 3-like 4 (Creb3l4), mRNA [NM_030080] |
KLA | 1.55 |
1.42 |
1.51 |
1.73 |
1.76 |
2.54 |
1.38 |
| ATP | 1.07 |
.81 |
.89 |
1.08 |
.94 |
1.08 |
1.08 |
| KLA/ATP | 1.44 |
1.38 |
1.44 |
1.25 |
1.30 |
1.26 |
2.24 |
|
Creb5 |  |
AK051306 |
12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130032G03 product:unclassifiable, full insert sequence. [AK051306] |
KLA | 2.18 |
2.13 |
2.42 |
1.97 |
1.57 |
1.94 |
1.98 |
| ATP | 1.11 |
1.09 |
1.47 |
1.74 |
1.36 |
1.44 |
1.62 |
| KLA/ATP | 2.55 |
2.77 |
3.02 |
3.15 |
2.51 |
2.52 |
2.61 |
|
Creb5 |  |
NM_172728 |
cAMP responsive element binding protein 5 (Creb5), mRNA [NM_172728] |
KLA | 3.70 |
3.60 |
2.84 |
2.39 |
1.92 |
2.81 |
1.84 |
| ATP | .92 |
.89 |
1.19 |
1.93 |
1.51 |
1.55 |
1.44 |
| KLA/ATP | 3.16 |
3.51 |
4.33 |
5.35 |
5.78 |
3.23 |
3.03 |
|
Crebl1 |  |
NM_017406 |
cAMP responsive element binding protein-like 1 (Crebl1), mRNA [NM_017406] |
KLA | 1.22 |
1.30 |
1.32 |
1.34 |
1.51 |
1.52 |
1.75 |
| ATP | 1.13 |
1.32 |
1.16 |
1.66 |
1.06 |
.93 |
1.54 |
| KLA/ATP | 1.37 |
1.25 |
1.21 |
1.74 |
1.04 |
1.01 |
2.07 |
|
Crtc2 |  |
NM_028881 |
CREB regulated transcription coactivator 2 (Crtc2), mRNA [NM_028881] |
KLA | 1.86 |
1.66 |
1.48 |
1.25 |
1.49 |
1.36 |
1.51 |
| ATP | 1.21 |
1.19 |
1.14 |
2.17 |
2.30 |
1.65 |
1.39 |
| KLA/ATP | 1.98 |
1.95 |
1.74 |
2.87 |
2.33 |
1.79 |
2.04 |
|
Csf1 |  |
NM_007778 |
colony stimulating factor 1 (macrophage) (Csf1), transcript variant 1, mRNA [NM_007778] |
KLA | 18.44 |
16.94 |
15.74 |
12.71 |
7.63 |
6.20 |
2.51 |
| ATP | 1.04 |
1.22 |
4.90 |
14.80 |
12.10 |
10.26 |
6.73 |
| KLA/ATP | 16.93 |
18.17 |
20.56 |
19.41 |
18.03 |
15.99 |
12.59 |
|
Csf1r |  |
NM_001037859 |
colony stimulating factor 1 receptor (Csf1r), mRNA [NM_001037859] |
KLA | .76 |
.81 |
.88 |
.67 |
.74 |
.78 |
.90 |
| ATP | 1.10 |
1.22 |
.88 |
1.10 |
.87 |
.78 |
1.28 |
| KLA/ATP | .97 |
.87 |
.63 |
.83 |
.51 |
.66 |
1.18 |
|
Csf3 |  |
NM_009971 |
colony stimulating factor 3 (granulocyte) (Csf3), mRNA [NM_009971] |
KLA | 1.44 |
1.56 |
2.06 |
2.25 |
2.97 |
1.58 |
1.55 |
| ATP | 1.04 |
1.05 |
1.14 |
2.18 |
4.85 |
7.52 |
1.83 |
| KLA/ATP | 1.54 |
1.93 |
2.57 |
4.75 |
3.85 |
3.95 |
7.39 |
|
Csf3r |  |
NM_007782 |
colony stimulating factor 3 receptor (granulocyte) (Csf3r), mRNA [NM_007782] |
KLA | 4.44 |
4.65 |
6.62 |
6.79 |
9.58 |
9.08 |
7.39 |
| ATP | 1.27 |
1.26 |
1.06 |
1.43 |
1.13 |
1.07 |
1.28 |
| KLA/ATP | 5.07 |
5.53 |
4.84 |
7.70 |
3.86 |
3.49 |
7.22 |
|
Ddit4 |  |
NM_029083 |
DNA-damage-inducible transcript 4 (Ddit4), mRNA [NM_029083] |
KLA | .59 |
.59 |
.64 |
.70 |
.58 |
.59 |
.52 |
| ATP | .53 |
.36 |
2.78 |
7.00 |
6.68 |
12.80 |
1.34 |
| KLA/ATP | .53 |
.68 |
5.47 |
12.86 |
9.74 |
8.93 |
2.95 |
|
E330026B 02Rik |  |
NM_172927 |
RIKEN cDNA E330026B02 gene (E330026B02Rik), transcript variant 2, mRNA [NM_172927] |
KLA | .94 |
.98 |
1.02 |
1.02 |
.97 |
1.05 |
.99 |
| ATP | .97 |
.94 |
.98 |
1.02 |
1.02 |
.99 |
1.02 |
| KLA/ATP | 1.01 |
.99 |
1.03 |
1.04 |
.96 |
.97 |
.94 |
|
EG629860
|  |
M17953 |
gb|Mouse Ig rearranged H-chain V-region mRNA VJ1 [M17953] |
KLA | .96 |
1.05 |
1.03 |
1.08 |
1.08 |
1.02 |
.98 |
| ATP | .97 |
.99 |
1.05 |
1.10 |
.95 |
.94 |
.91 |
| KLA/ATP | .96 |
.94 |
.97 |
1.04 |
.97 |
1.01 |
.89 |
|
Efna1 |  |
NM_010107 |
ephrin A1 (Efna1), mRNA [NM_010107] |
KLA | 1.04 |
.94 |
.87 |
.95 |
.96 |
.92 |
.89 |
| ATP | 1.01 |
1.04 |
.99 |
.93 |
.90 |
1.05 |
.94 |
| KLA/ATP | .84 |
.93 |
.99 |
.91 |
.91 |
.86 |
.90 |
|
Efna2 |  |
NM_007909 |
ephrin A2 (Efna2), mRNA [NM_007909] |
KLA | 2.64 |
2.43 |
2.68 |
2.06 |
1.56 |
1.06 |
.92 |
| ATP | 1.00 |
1.20 |
1.11 |
1.12 |
1.04 |
1.08 |
.94 |
| KLA/ATP | 2.21 |
2.52 |
2.57 |
2.28 |
1.62 |
1.40 |
1.15 |
|
Efna3 |  |
AK020438 |
12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430025D14 product:ephrin A3, full insert sequence. [AK020438] |
KLA | .99 |
.98 |
.97 |
.96 |
.94 |
.98 |
.95 |
| ATP | .98 |
1.05 |
.98 |
.96 |
1.00 |
1.00 |
1.02 |
| KLA/ATP | 1.01 |
1.03 |
1.04 |
1.03 |
.99 |
1.04 |
.98 |
|
Efna4 |  |
NM_007910 |
ephrin A4 (Efna4), mRNA [NM_007910] |
KLA | 1.01 |
.99 |
1.01 |
1.01 |
1.05 |
1.07 |
1.02 |
| ATP | .99 |
.98 |
.98 |
1.04 |
.98 |
.99 |
1.01 |
| KLA/ATP | .97 |
1.00 |
1.06 |
.97 |
.86 |
1.04 |
1.02 |
|
Efna5 |  |
NM_010109 |
ephrin A5 (Efna5), transcript variant 2, mRNA [NM_010109] |
KLA | 1.04 |
1.09 |
1.05 |
.98 |
.96 |
1.02 |
.97 |
| ATP | .92 |
1.02 |
1.07 |
.99 |
1.00 |
1.09 |
1.04 |
| KLA/ATP | .95 |
.93 |
1.02 |
1.00 |
1.04 |
1.00 |
1.01 |
|
Efna5 |  |
NM_207654 |
ephrin A5 (Efna5), transcript variant 1, mRNA [NM_207654] |
KLA | .96 |
.99 |
1.07 |
1.05 |
1.04 |
1.06 |
1.10 |
| ATP | .97 |
.90 |
1.05 |
1.03 |
1.02 |
1.00 |
1.04 |
| KLA/ATP | 1.07 |
1.02 |
1.08 |
1.03 |
1.05 |
1.14 |
1.01 |
|
Egf |  |
NM_010113 |
epidermal growth factor (Egf), mRNA [NM_010113] |
KLA | .89 |
.90 |
.81 |
.83 |
.83 |
.86 |
.92 |
| ATP | 1.03 |
1.03 |
.95 |
.84 |
.67 |
.79 |
.88 |
| KLA/ATP | .86 |
.86 |
.77 |
.77 |
.69 |
.78 |
.83 |
|
Egfr |  |
NM_007912 |
epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] |
KLA | 1.10 |
1.07 |
1.14 |
1.11 |
1.08 |
1.03 |
.90 |
| ATP | .99 |
1.00 |
1.04 |
.98 |
.97 |
1.15 |
1.14 |
| KLA/ATP | 1.07 |
1.10 |
1.16 |
1.08 |
1.01 |
.97 |
.94 |
|
Egfr |  |
NM_207655 |
epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] |
KLA | 1.57 |
1.44 |
1.47 |
1.31 |
.96 |
.92 |
.76 |
| ATP | .97 |
.93 |
1.10 |
1.00 |
1.41 |
2.97 |
.86 |
| KLA/ATP | 1.44 |
1.50 |
1.61 |
1.30 |
1.14 |
1.21 |
.82 |
|
Eif4b |  |
NM_145625 |
eukaryotic translation initiation factor 4B (Eif4b), mRNA [NM_145625] |
KLA | .93 |
.95 |
.95 |
.80 |
.75 |
.73 |
.97 |
| ATP | 1.08 |
1.19 |
1.04 |
1.43 |
1.34 |
1.48 |
1.04 |
| KLA/ATP | 1.13 |
1.07 |
.93 |
1.10 |
.98 |
1.19 |
1.55 |
|
Eif4e |  |
NM_007917 |
eukaryotic translation initiation factor 4E (Eif4e), mRNA [NM_007917] |
KLA | 1.22 |
1.06 |
.94 |
.97 |
.83 |
.85 |
1.18 |
| ATP | 1.00 |
1.01 |
1.27 |
1.27 |
2.61 |
2.08 |
.97 |
| KLA/ATP | .95 |
1.04 |
1.37 |
1.16 |
1.50 |
1.28 |
.73 |
|
Eif4e2 |  |
NM_001039169 |
eukaryotic translation initiation factor 4E member 2 (Eif4e2), transcript variant 2, mRNA [NM_001039169] |
KLA | 1.53 |
1.51 |
1.54 |
1.52 |
1.55 |
1.49 |
1.55 |
| ATP | 1.02 |
1.08 |
1.12 |
1.45 |
1.61 |
1.51 |
1.15 |
| KLA/ATP | 1.56 |
1.60 |
1.59 |
1.90 |
1.90 |
1.75 |
1.68 |
|
Eif4e2 |  |
NM_023314 |
eukaryotic translation initiation factor 4E member 2 (Eif4e2), transcript variant 3, mRNA [NM_023314] |
KLA | 1.42 |
1.40 |
1.43 |
1.35 |
1.58 |
1.65 |
1.42 |
| ATP | 1.06 |
1.06 |
1.04 |
.98 |
1.41 |
2.07 |
2.04 |
| KLA/ATP | 1.46 |
1.48 |
1.40 |
1.45 |
1.64 |
2.12 |
2.30 |
|
Eif4ebp1
|  |
NM_007918 |
eukaryotic translation initiation factor 4E binding protein 1 (Eif4ebp1), mRNA [NM_007918] |
KLA | .66 |
.64 |
.59 |
.67 |
.81 |
.97 |
.97 |
| ATP | .97 |
.94 |
1.10 |
1.05 |
1.99 |
1.60 |
.91 |
| KLA/ATP | .62 |
.61 |
.68 |
.68 |
1.50 |
1.24 |
.95 |
|
Epha2 |  |
NM_010139 |
Eph receptor A2 (Epha2), mRNA [NM_010139] |
KLA | .88 |
.76 |
.65 |
.75 |
.84 |
.89 |
.83 |
| ATP | 1.08 |
1.14 |
1.35 |
3.86 |
2.84 |
1.93 |
1.07 |
| KLA/ATP | .82 |
.84 |
.78 |
1.59 |
1.58 |
1.62 |
1.15 |
|
Epo |  |
NM_007942 |
erythropoietin (Epo), mRNA [NM_007942] |
KLA | 1.00 |
1.05 |
1.08 |
1.01 |
1.03 |
1.08 |
1.04 |
| ATP | .95 |
.97 |
.97 |
1.04 |
1.02 |
.99 |
1.01 |
| KLA/ATP | 1.03 |
1.01 |
.97 |
1.00 |
1.00 |
1.10 |
1.00 |
|
Epor |  |
NM_010149 |
erythropoietin receptor (Epor), mRNA [NM_010149] |
KLA | .57 |
.56 |
.59 |
.66 |
.59 |
.52 |
.36 |
| ATP | 1.06 |
1.01 |
1.00 |
.95 |
.73 |
.52 |
.40 |
| KLA/ATP | .57 |
.53 |
.70 |
.66 |
.72 |
.62 |
.34 |
|
F2r |  |
NM_010169 |
coagulation factor II (thrombin) receptor (F2r), mRNA [NM_010169] |
KLA | 3.73 |
3.81 |
3.68 |
3.00 |
2.75 |
1.49 |
1.01 |
| ATP | .98 |
1.02 |
1.25 |
1.24 |
1.31 |
1.63 |
1.16 |
| KLA/ATP | 3.51 |
4.05 |
3.49 |
3.00 |
2.48 |
1.69 |
1.23 |
|
Fasl |  |
NM_010177 |
Fas ligand (TNF superfamily, member 6) (Fasl), mRNA [NM_010177] |
KLA | 1.03 |
1.01 |
1.03 |
1.02 |
1.01 |
1.01 |
1.00 |
| ATP | 1.00 |
.99 |
1.04 |
1.21 |
1.18 |
1.20 |
1.01 |
| KLA/ATP | 1.00 |
1.02 |
1.07 |
1.16 |
1.18 |
1.23 |
1.00 |
|
Fgf1 |  |
NM_010197 |
fibroblast growth factor 1 (Fgf1), mRNA [NM_010197] |
KLA | 1.07 |
.99 |
.99 |
1.00 |
1.03 |
.97 |
.99 |
| ATP | 1.01 |
1.03 |
1.01 |
.95 |
.95 |
.98 |
.88 |
| KLA/ATP | 1.03 |
.99 |
.97 |
.99 |
.98 |
.94 |
1.01 |
|
Fgf10 |  |
NM_008002 |
fibroblast growth factor 10 (Fgf10), mRNA [NM_008002] |
KLA | .99 |
.98 |
1.02 |
1.00 |
1.02 |
1.02 |
1.02 |
| ATP | 1.03 |
1.02 |
1.00 |
1.00 |
1.00 |
.99 |
.99 |
| KLA/ATP | 1.01 |
1.00 |
1.04 |
.99 |
1.00 |
1.02 |
1.01 |
|
Fgf11 |  |
BC066859 |
fibroblast growth factor 11, mRNA (cDNA clone MGC:76712 IMAGE:30101881), complete cds [BC066859] |
KLA | .64 |
.61 |
.55 |
.58 |
.51 |
.48 |
.77 |
| ATP | 1.00 |
.96 |
.78 |
.78 |
.63 |
.44 |
.48 |
| KLA/ATP | .64 |
.63 |
.59 |
.56 |
.54 |
.42 |
.40 |
|
Fgf11 |  |
NM_010198 |
fibroblast growth factor 11 (Fgf11), mRNA [NM_010198] |
KLA | .99 |
1.02 |
1.05 |
1.04 |
1.01 |
1.03 |
1.07 |
| ATP | .95 |
1.02 |
1.02 |
1.07 |
.98 |
1.01 |
1.07 |
| KLA/ATP | 1.01 |
1.01 |
1.08 |
.96 |
.97 |
.95 |
1.01 |
|
Fgf12 |  |
NM_183064 |
fibroblast growth factor 12 (Fgf12), transcript variant 1, mRNA [NM_183064] |
KLA | .96 |
.97 |
1.05 |
.99 |
.97 |
1.01 |
1.01 |
| ATP | .93 |
.97 |
.97 |
.97 |
.99 |
.95 |
1.00 |
| KLA/ATP | 1.02 |
1.05 |
1.10 |
1.02 |
.95 |
1.01 |
.95 |
|
Fgf13 |  |
NM_010200 |
fibroblast growth factor 13 (Fgf13), mRNA [NM_010200] |
KLA | .91 |
.92 |
.93 |
.84 |
.77 |
.66 |
.75 |
| ATP | 1.09 |
1.14 |
1.03 |
1.11 |
1.06 |
.68 |
.78 |
| KLA/ATP | .98 |
1.02 |
.86 |
.90 |
.78 |
.70 |
.79 |
|
Fgf14 |  |
NM_010201 |
fibroblast growth factor 14 (Fgf14), transcript variant 1, mRNA [NM_010201] |
KLA | 1.04 |
1.05 |
1.02 |
1.04 |
1.03 |
1.05 |
1.03 |
| ATP | .99 |
1.08 |
1.04 |
1.00 |
.99 |
.98 |
1.04 |
| KLA/ATP | 1.00 |
1.00 |
1.08 |
1.00 |
1.04 |
1.01 |
1.03 |
|
Fgf14 |  |
NM_207667 |
fibroblast growth factor 14 (Fgf14), transcript variant 2, mRNA [NM_207667] |
KLA | 1.04 |
1.01 |
.98 |
.93 |
.96 |
.96 |
.97 |
| ATP | 1.04 |
1.10 |
.94 |
.87 |
1.03 |
.99 |
.96 |
| KLA/ATP | .86 |
.94 |
1.03 |
.89 |
1.00 |
.90 |
1.03 |
|
Fgf15 |  |
NM_008003 |
fibroblast growth factor 15 (Fgf15), mRNA [NM_008003] |
KLA | 1.00 |
1.00 |
.95 |
.98 |
.92 |
.96 |
1.01 |
| ATP | .99 |
1.01 |
.98 |
.98 |
.93 |
.95 |
.97 |
| KLA/ATP | .98 |
1.01 |
1.02 |
1.03 |
.97 |
.97 |
1.00 |
|
Fgf16 |  |
NM_030614 |
fibroblast growth factor 16 (Fgf16), mRNA [NM_030614] |
KLA | 1.00 |
.97 |
.99 |
1.02 |
1.04 |
.97 |
.97 |
| ATP | 1.02 |
.99 |
.99 |
1.02 |
1.12 |
1.01 |
1.02 |
| KLA/ATP | 1.06 |
1.02 |
.99 |
1.01 |
1.00 |
1.10 |
1.03 |
|
Fgf17 |  |
NM_008004 |
fibroblast growth factor 17 (Fgf17), mRNA [NM_008004] |
KLA | .97 |
1.03 |
.98 |
1.00 |
.97 |
.97 |
.86 |
| ATP | .99 |
.96 |
.99 |
.90 |
1.02 |
1.01 |
1.01 |
| KLA/ATP | .99 |
.91 |
1.08 |
.99 |
.99 |
.98 |
.99 |
|
Fgf18 |  |
NM_008005 |
fibroblast growth factor 18 (Fgf18), mRNA [NM_008005] |
KLA | 1.17 |
1.18 |
1.16 |
1.12 |
1.03 |
1.13 |
1.04 |
| ATP | .96 |
.98 |
2.47 |
12.57 |
2.76 |
1.56 |
1.03 |
| KLA/ATP | 1.01 |
1.15 |
2.33 |
10.13 |
2.80 |
1.79 |
1.02 |
|
Fgf2 |  |
NM_008006 |
fibroblast growth factor 2 (Fgf2), mRNA [NM_008006] |
KLA | 1.02 |
1.01 |
1.00 |
1.03 |
1.01 |
1.02 |
1.01 |
| ATP | .99 |
1.01 |
1.00 |
1.02 |
1.01 |
1.01 |
1.00 |
| KLA/ATP | 1.00 |
1.01 |
.98 |
1.01 |
1.02 |
1.03 |
1.01 |
|
Fgf20 |  |
NM_030610 |
fibroblast growth factor 20 (Fgf20), mRNA [NM_030610] |
KLA | .97 |
1.08 |
.99 |
1.00 |
.97 |
1.00 |
.97 |
| ATP | 1.03 |
.95 |
.97 |
1.05 |
.98 |
.97 |
1.00 |
| KLA/ATP | .99 |
.99 |
1.06 |
1.04 |
1.02 |
.92 |
.96 |
|
Fgf21 |  |
NM_020013 |
fibroblast growth factor 21 (Fgf21), mRNA [NM_020013] |
KLA | 1.02 |
1.03 |
.87 |
1.04 |
1.00 |
1.01 |
1.00 |
| ATP | 1.04 |
.97 |
1.00 |
1.02 |
.96 |
1.05 |
1.02 |
| KLA/ATP | 1.08 |
1.00 |
1.00 |
1.00 |
1.03 |
1.02 |
.99 |
|
Fgf22 |  |
AK008922 |
adult male stomach cDNA, RIKEN full-length enriched library, clone:2210414E06 product:FIBROBLAST GROWTH FACTOR-22 PRECURSOR (FGF-22) homolog [Mus musculus], full insert sequence [AK008922] |
KLA | .90 |
.94 |
.95 |
1.04 |
1.03 |
.94 |
.97 |
| ATP | 1.04 |
1.01 |
.98 |
.93 |
.93 |
.95 |
.88 |
| KLA/ATP | .98 |
.97 |
.97 |
1.01 |
.95 |
.92 |
.95 |
|
Fgf22 |  |
NM_023304 |
fibroblast growth factor 22 (Fgf22), mRNA [NM_023304] |
KLA | .99 |
.94 |
1.01 |
.95 |
.97 |
.89 |
.99 |
| ATP | 1.00 |
.95 |
1.00 |
.96 |
.97 |
.93 |
.98 |
| KLA/ATP | .91 |
1.00 |
1.01 |
.92 |
.95 |
.98 |
.97 |
|
Fgf23 |  |
NM_022657 |
fibroblast growth factor 23 (Fgf23), mRNA [NM_022657] |
KLA | 1.32 |
1.39 |
1.27 |
1.22 |
1.07 |
1.03 |
1.14 |
| ATP | .95 |
1.00 |
1.05 |
1.07 |
1.05 |
1.02 |
.96 |
| KLA/ATP | 1.32 |
1.39 |
1.37 |
1.22 |
1.01 |
1.00 |
.90 |
|
Fgf3 |  |
NM_008007 |
fibroblast growth factor 3 (Fgf3), mRNA [NM_008007] |
KLA | 1.03 |
1.05 |
1.00 |
.97 |
1.01 |
.98 |
.97 |
| ATP | 1.01 |
1.00 |
.97 |
1.03 |
.98 |
1.03 |
.97 |
| KLA/ATP | .98 |
1.00 |
1.01 |
1.03 |
1.03 |
1.00 |
.99 |
|
Fgf5 |  |
NM_010203 |
fibroblast growth factor 5 (Fgf5), mRNA [NM_010203] |
KLA | 1.02 |
1.02 |
1.00 |
1.03 |
.97 |
1.05 |
.99 |
| ATP | 1.02 |
1.00 |
1.03 |
.97 |
.99 |
.97 |
1.04 |
| KLA/ATP | 1.05 |
.92 |
1.01 |
1.00 |
1.11 |
.96 |
.97 |
|
Fgf6 |  |
M92416 |
fibroblast growth factor (Fgf6) mRNA, 3 end [M92416] |
KLA | 1.09 |
1.07 |
1.00 |
1.06 |
.97 |
1.01 |
.96 |
| ATP | 1.02 |
1.02 |
1.06 |
1.02 |
.93 |
.99 |
.98 |
| KLA/ATP | 1.04 |
.99 |
1.00 |
.99 |
1.00 |
1.00 |
1.03 |
|
Fgf6 |  |
NM_010204 |
fibroblast growth factor 6 (Fgf6), mRNA [NM_010204] |
KLA | 1.00 |
.96 |
1.06 |
.96 |
.96 |
1.00 |
.91 |
| ATP | .94 |
1.00 |
.89 |
.95 |
1.01 |
.92 |
1.00 |
| KLA/ATP | .99 |
1.06 |
1.06 |
.86 |
1.00 |
.95 |
1.00 |
|
Fgf7 |  |
NM_008008 |
fibroblast growth factor 7 (Fgf7), mRNA [NM_008008] |
KLA | 1.02 |
1.02 |
1.02 |
1.03 |
1.05 |
1.11 |
1.04 |
| ATP | 1.00 |
1.01 |
1.11 |
1.15 |
1.05 |
1.04 |
1.06 |
| KLA/ATP | .99 |
.96 |
.83 |
1.10 |
1.15 |
1.26 |
1.21 |
|
Fgf8 |  |
BC048734 |
fibroblast growth factor 8, mRNA (cDNA clone MGC:59627 IMAGE:6513131), complete cds [BC048734] |
KLA | .96 |
.95 |
1.03 |
.96 |
1.06 |
.97 |
.96 |
| ATP | 1.08 |
.94 |
1.07 |
1.10 |
1.00 |
.93 |
1.06 |
| KLA/ATP | 1.03 |
1.02 |
1.04 |
.96 |
1.04 |
.94 |
.94 |
|
Fgf8 |  |
NM_010205 |
fibroblast growth factor 8 (Fgf8), mRNA [NM_010205] |
KLA | 1.00 |
1.00 |
1.03 |
1.04 |
1.04 |
1.07 |
1.09 |
| ATP | 1.01 |
1.01 |
1.11 |
1.14 |
1.11 |
1.09 |
1.05 |
| KLA/ATP | 1.00 |
1.04 |
1.14 |
1.18 |
1.15 |
1.09 |
1.04 |
|
Fgf9 |  |
NM_013518 |
fibroblast growth factor 9 (Fgf9), mRNA [NM_013518] |
KLA | 1.04 |
1.07 |
1.07 |
1.12 |
.97 |
.96 |
.91 |
| ATP | 1.02 |
1.08 |
.98 |
1.00 |
.94 |
.99 |
.92 |
| KLA/ATP | 1.04 |
1.03 |
1.03 |
1.00 |
.93 |
.93 |
.89 |
|
Fgfr1 |  |
M28998 |
gb|Mouse basic fibroblast growth factor receptor (bFGF-R) mRNA, complete cds. [M28998] |
KLA | .82 |
.79 |
.73 |
.66 |
.50 |
.55 |
.65 |
| ATP | 1.01 |
1.08 |
.86 |
.90 |
1.29 |
1.24 |
1.52 |
| KLA/ATP | .85 |
.82 |
.71 |
.71 |
.63 |
.80 |
.85 |
|
Fgfr1 |  |
NM_010206 |
fibroblast growth factor receptor 1 (Fgfr1), transcript variant 1, mRNA [NM_010206] |
KLA | .92 |
.86 |
.73 |
.82 |
.79 |
.85 |
.84 |
| ATP | 1.01 |
1.06 |
.92 |
.92 |
1.18 |
1.02 |
1.22 |
| KLA/ATP | .83 |
.83 |
.79 |
.76 |
.83 |
.83 |
.92 |
|
Fgfr2 |  |
NM_010207 |
fibroblast growth factor receptor 2 (Fgfr2), transcript variant 1, mRNA [NM_010207] |
KLA | 1.01 |
.98 |
1.00 |
1.01 |
.98 |
1.00 |
.99 |
| ATP | 1.00 |
1.03 |
1.05 |
1.03 |
1.01 |
1.01 |
1.00 |
| KLA/ATP | 1.00 |
1.01 |
1.04 |
1.01 |
.99 |
1.02 |
1.03 |
|
Fgfr3 |  |
NM_008010 |
fibroblast growth factor receptor 3 (Fgfr3), mRNA [NM_008010] |
KLA | 1.09 |
1.15 |
1.05 |
1.10 |
1.02 |
1.05 |
1.12 |
| ATP | 1.05 |
.94 |
.98 |
.87 |
.91 |
.95 |
.92 |
| KLA/ATP | 1.13 |
1.11 |
1.10 |
.91 |
.92 |
.93 |
.92 |
|
Fgfr4 |  |
AF127140 |
fibroblast growth factor receptor 4 splice variant 17b (Fgfr4) mRNA, partial cds. [AF127140] |
KLA | .96 |
.97 |
1.06 |
.97 |
1.05 |
1.05 |
1.08 |
| ATP | 1.02 |
.98 |
1.07 |
1.23 |
1.15 |
1.18 |
1.31 |
| KLA/ATP | .91 |
1.02 |
1.08 |
1.16 |
1.07 |
1.05 |
1.23 |
|
Fgfr4 |  |
NM_008011 |
fibroblast growth factor receptor 4 (Fgfr4), mRNA [NM_008011] |
KLA | 1.08 |
1.11 |
1.09 |
1.06 |
.99 |
1.06 |
1.03 |
| ATP | 1.05 |
.96 |
1.17 |
1.06 |
1.10 |
1.04 |
1.01 |
| KLA/ATP | 1.03 |
.98 |
1.10 |
1.06 |
1.05 |
1.06 |
1.04 |
|
Figf |  |
NM_010216 |
c-fos induced growth factor (Figf), mRNA [NM_010216] |
KLA | .92 |
.95 |
.93 |
.87 |
.82 |
.87 |
.77 |
| ATP | 1.03 |
1.04 |
1.06 |
.90 |
1.13 |
2.02 |
.78 |
| KLA/ATP | .92 |
.94 |
.97 |
.85 |
.97 |
1.10 |
.92 |
|
Flt1 |  |
NM_010228 |
FMS-like tyrosine kinase 1 (Flt1), mRNA [NM_010228] |
KLA | 3.02 |
2.74 |
2.92 |
3.54 |
3.71 |
3.82 |
1.43 |
| ATP | .88 |
.85 |
1.07 |
.85 |
.94 |
1.31 |
1.16 |
| KLA/ATP | 2.60 |
2.99 |
3.08 |
2.13 |
2.23 |
2.00 |
2.59 |
|
Flt4 |  |
NM_008029 |
FMS-like tyrosine kinase 4 (Flt4), mRNA [NM_008029] |
KLA | 1.04 |
1.02 |
1.01 |
1.00 |
1.10 |
1.01 |
1.01 |
| ATP | 1.02 |
1.08 |
1.07 |
.99 |
.95 |
.97 |
1.02 |
| KLA/ATP | 1.08 |
1.06 |
1.00 |
1.02 |
.99 |
1.07 |
1.02 |
|
Fn1 |  |
NM_010233 |
fibronectin 1 (Fn1), mRNA [NM_010233] |
KLA | 1.23 |
1.30 |
1.38 |
1.12 |
1.16 |
1.00 |
.78 |
| ATP | 1.02 |
1.19 |
1.25 |
1.56 |
1.33 |
1.05 |
.95 |
| KLA/ATP | 1.36 |
1.51 |
1.34 |
1.70 |
1.20 |
1.06 |
.93 |
|
Foxo3a |  |
AK079567 |
adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230087I01 product:unclassifiable, full insert sequence. [AK079567] |
KLA | .82 |
.81 |
.91 |
.83 |
.86 |
.86 |
.81 |
| ATP | .98 |
1.00 |
1.13 |
1.03 |
.97 |
.90 |
.82 |
| KLA/ATP | .86 |
.80 |
.90 |
.99 |
1.07 |
.84 |
.73 |
|
Foxo3a |  |
NM_019740 |
forkhead box O3a (Foxo3a), mRNA [NM_019740] |
KLA | .94 |
.92 |
.86 |
.97 |
.87 |
1.04 |
1.04 |
| ATP | .99 |
1.09 |
1.06 |
.97 |
.96 |
1.07 |
1.15 |
| KLA/ATP | .90 |
.79 |
.90 |
.99 |
.95 |
1.04 |
1.11 |
|
Frap1 |  |
NM_020009 |
FK506 binding protein 12-rapamycin associated protein 1 (Frap1), mRNA [NM_020009] |
KLA | 1.37 |
1.32 |
1.46 |
1.57 |
1.83 |
1.29 |
1.28 |
| ATP | 1.12 |
1.07 |
.95 |
.91 |
.80 |
.77 |
1.03 |
| KLA/ATP | 1.45 |
1.51 |
1.50 |
1.11 |
.89 |
.87 |
1.01 |
|
G6pc |  |
NM_008061 |
glucose-6-phosphatase, catalytic (G6pc), mRNA [NM_008061] |
KLA | .96 |
.94 |
1.04 |
1.07 |
1.09 |
1.06 |
1.02 |
| ATP | .98 |
1.05 |
1.09 |
1.04 |
1.05 |
1.00 |
1.01 |
| KLA/ATP | 1.03 |
1.05 |
1.06 |
.96 |
1.02 |
1.00 |
.99 |
|
G6pc2 |  |
NM_021331 |
glucose-6-phosphatase, catalytic, 2 (G6pc2), mRNA [NM_021331] |
KLA | .99 |
1.03 |
1.00 |
.98 |
.95 |
1.02 |
.98 |
| ATP | .95 |
1.06 |
.97 |
1.08 |
1.16 |
1.26 |
1.04 |
| KLA/ATP | .94 |
.99 |
1.05 |
6.99 |
3.55 |
1.48 |
1.11 |
|
G6pc3 |  |
NM_175935 |
glucose 6 phosphatase, catalytic, 3 (G6pc3), mRNA [NM_175935] |
KLA | .88 |
.89 |
.89 |
.80 |
.75 |
.68 |
.88 |
| ATP | .99 |
1.05 |
.95 |
1.14 |
.92 |
.64 |
.81 |
| KLA/ATP | .92 |
.90 |
.79 |
.94 |
.70 |
.62 |
.58 |
|
Gbl |  |
NM_019988 |
G protein beta subunit-like (Gbl), mRNA [NM_019988] |
KLA | .43 |
.37 |
.36 |
.45 |
.56 |
.77 |
1.10 |
| ATP | .94 |
.79 |
.71 |
.49 |
.56 |
1.42 |
.90 |
| KLA/ATP | .40 |
.37 |
.35 |
.29 |
.49 |
1.30 |
.86 |
|
Gh |  |
NM_008117 |
growth hormone (Gh), mRNA [NM_008117] |
KLA | 1.02 |
1.03 |
1.01 |
.98 |
.98 |
.94 |
.98 |
| ATP | .94 |
1.02 |
1.06 |
1.20 |
.99 |
.95 |
.96 |
| KLA/ATP | .97 |
1.03 |
1.03 |
1.09 |
.96 |
1.00 |
1.05 |
|
Ghr |  |
AK053579 |
0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130111P21 product:growth hormone receptor, full insert sequence. [AK053579] |
KLA | 1.10 |
1.07 |
1.09 |
1.01 |
1.03 |
.96 |
1.02 |
| ATP | 1.04 |
1.01 |
1.06 |
.96 |
1.03 |
.96 |
1.02 |
| KLA/ATP | 1.08 |
1.15 |
1.15 |
1.04 |
1.02 |
1.07 |
1.03 |
|
Ghr |  |
NM_010284 |
growth hormone receptor (Ghr), transcript variant 1, mRNA [NM_010284] |
KLA | 1.09 |
1.10 |
1.29 |
1.31 |
1.23 |
1.09 |
.97 |
| ATP | 1.00 |
1.02 |
1.03 |
1.02 |
.93 |
.96 |
.97 |
| KLA/ATP | 1.17 |
1.20 |
1.15 |
1.15 |
1.07 |
.96 |
.96 |
|
Gnb1 |  |
NM_008142 |
guanine nucleotide binding protein (G protein), beta 1 (Gnb1), mRNA [NM_008142] |
KLA | 1.11 |
1.18 |
1.22 |
1.19 |
1.29 |
1.32 |
1.76 |
| ATP | 1.02 |
1.09 |
.84 |
.99 |
.97 |
.89 |
1.22 |
| KLA/ATP | 1.20 |
1.25 |
.85 |
1.01 |
.86 |
.91 |
1.57 |
|
Gnb2 |  |
NM_010312 |
guanine nucleotide binding protein (G protein), beta 2 (Gnb2), mRNA [NM_010312] |
KLA | .94 |
.98 |
.94 |
1.08 |
1.23 |
1.32 |
1.16 |
| ATP | 1.04 |
.96 |
.59 |
.64 |
.59 |
.76 |
1.18 |
| KLA/ATP | 1.02 |
.84 |
.62 |
.64 |
.61 |
.89 |
1.36 |
|
Gnb3 |  |
NM_013530 |
guanine nucleotide binding protein (G protein), beta 3 (Gnb3), mRNA [NM_013530] |
KLA | .99 |
1.00 |
.98 |
1.03 |
.94 |
.99 |
.96 |
| ATP | 1.01 |
1.02 |
.97 |
.95 |
1.01 |
.97 |
.92 |
| KLA/ATP | .99 |
1.02 |
1.02 |
.98 |
.99 |
.85 |
.99 |
|
Gnb4 |  |
AK165084 |
2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330002E21 product:guanine nucleotide binding protein, beta 4, full insert sequence [AK165084] |
KLA | 4.61 |
4.10 |
4.23 |
2.41 |
2.25 |
1.59 |
.93 |
| ATP | 1.21 |
1.17 |
1.04 |
.81 |
2.92 |
1.50 |
1.03 |
| KLA/ATP | 5.86 |
6.56 |
3.60 |
1.68 |
5.62 |
3.00 |
1.37 |
|
Gnb4 |  |
NM_013531 |
guanine nucleotide binding protein (G protein), beta 4 (Gnb4), mRNA [NM_013531] |
KLA | 8.41 |
8.09 |
10.57 |
9.44 |
6.06 |
2.97 |
.92 |
| ATP | 1.07 |
1.04 |
1.09 |
.87 |
1.48 |
2.10 |
1.18 |
| KLA/ATP | 8.14 |
8.93 |
9.12 |
7.69 |
5.03 |
5.11 |
2.37 |
|
Gnb5 |  |
NM_010313 |
guanine nucleotide binding protein (G protein), beta 5 (Gnb5), transcript variant 1, mRNA [NM_010313] |
KLA | .68 |
.75 |
.67 |
.66 |
.53 |
.50 |
.65 |
| ATP | 1.03 |
1.08 |
1.09 |
1.14 |
.72 |
.54 |
.77 |
| KLA/ATP | .73 |
.70 |
.71 |
.73 |
.61 |
.65 |
.58 |
|
Gng10 |  |
NM_025277 |
guanine nucleotide binding protein (G protein), gamma 10 (Gng10), mRNA [NM_025277] |
KLA | .95 |
.95 |
.86 |
.83 |
.70 |
.53 |
.43 |
| ATP | .93 |
1.03 |
1.17 |
1.21 |
.97 |
.60 |
.52 |
| KLA/ATP | .84 |
.91 |
.93 |
.99 |
.79 |
.47 |
.24 |
|
Gng11 |  |
NM_025331 |
guanine nucleotide binding protein (G protein), gamma 11 (Gng11), mRNA [NM_025331] |
KLA | 1.30 |
1.26 |
1.44 |
1.54 |
1.26 |
1.42 |
1.90 |
| ATP | .88 |
.78 |
1.26 |
1.14 |
.90 |
.64 |
1.60 |
| KLA/ATP | 1.11 |
1.18 |
1.81 |
1.55 |
1.81 |
1.75 |
3.05 |
|
Gng12 |  |
NM_025278 |
guanine nucleotide binding protein (G protein), gamma 12 (Gng12), mRNA [NM_025278] |
KLA | 2.21 |
2.23 |
2.48 |
2.62 |
2.47 |
2.28 |
1.68 |
| ATP | 1.02 |
1.02 |
1.09 |
1.10 |
1.20 |
1.32 |
1.01 |
| KLA/ATP | 2.10 |
2.17 |
2.38 |
2.40 |
1.91 |
1.60 |
1.77 |
|
Gng13 |  |
NM_022422 |
guanine nucleotide binding protein (G protein), gamma 13 (Gng13), mRNA [NM_022422] |
KLA | 1.04 |
1.04 |
.94 |
1.00 |
1.00 |
1.05 |
.96 |
| ATP | 1.07 |
1.05 |
1.02 |
.94 |
.98 |
1.03 |
1.01 |
| KLA/ATP | 1.01 |
.99 |
1.05 |
1.01 |
1.01 |
.98 |
1.02 |
|
Gng2 |  |
NM_010315 |
guanine nucleotide binding protein (G protein), gamma 2 (Gng2), transcript variant 1, mRNA [NM_010315] |
KLA | .79 |
.81 |
.81 |
.82 |
.67 |
.57 |
.75 |
| ATP | 1.02 |
1.01 |
1.13 |
1.35 |
1.48 |
1.01 |
1.31 |
| KLA/ATP | .79 |
.86 |
.97 |
1.05 |
1.29 |
1.00 |
.84 |
|
Gng3 |  |
NM_010316 |
guanine nucleotide binding protein (G protein), gamma 3 (Gng3), mRNA [NM_010316] |
KLA | 1.00 |
.98 |
1.02 |
.95 |
.99 |
1.00 |
1.06 |
| ATP | .98 |
1.05 |
.99 |
1.03 |
1.05 |
1.03 |
.97 |
| KLA/ATP | 1.01 |
1.00 |
1.07 |
1.01 |
1.04 |
1.04 |
1.05 |
|
Gng4 |  |
NM_010317 |
guanine nucleotide binding protein (G protein), gamma 4 (Gng4), mRNA [NM_010317] |
KLA | 1.27 |
1.26 |
1.47 |
1.30 |
1.15 |
1.13 |
.82 |
| ATP | 1.05 |
.97 |
1.07 |
1.62 |
3.97 |
3.46 |
1.24 |
| KLA/ATP | 1.35 |
1.32 |
1.37 |
1.35 |
1.64 |
2.18 |
1.56 |
|
Gng5 |  |
NM_010318 |
guanine nucleotide binding protein (G protein), gamma 5 (Gng5), mRNA [NM_010318] |
KLA | .94 |
.84 |
.80 |
1.12 |
.98 |
1.11 |
1.29 |
| ATP | 1.07 |
1.01 |
1.07 |
1.05 |
1.17 |
1.52 |
1.01 |
| KLA/ATP | .83 |
.94 |
1.27 |
1.17 |
1.19 |
1.35 |
1.36 |
|
Gng7 |  |
NM_001038655 |
guanine nucleotide binding protein (G protein), gamma 7 (Gng7), transcript variant 1, mRNA [NM_001038655] |
KLA | .92 |
.96 |
.87 |
.91 |
.83 |
.98 |
.98 |
| ATP | 1.04 |
1.06 |
.98 |
.95 |
.81 |
.77 |
.75 |
| KLA/ATP | .97 |
.95 |
.81 |
.91 |
.79 |
.77 |
.81 |
|
Gng8 |  |
NM_010320 |
guanine nucleotide binding protein (G protein), gamma 8 (Gng8), mRNA [NM_010320] |
KLA | .93 |
.93 |
.95 |
.96 |
.90 |
.88 |
1.09 |
| ATP | .95 |
.90 |
1.01 |
.92 |
1.04 |
1.01 |
1.05 |
| KLA/ATP | .97 |
1.03 |
.99 |
.90 |
1.10 |
.99 |
1.04 |
|
Gngt1 |  |
NM_010314 |
guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 1 (Gngt1), mRNA [NM_010314] |
KLA | 1.06 |
.99 |
.95 |
.98 |
1.03 |
1.10 |
.98 |
| ATP | .96 |
1.02 |
1.03 |
1.03 |
.94 |
1.06 |
.95 |
| KLA/ATP | .98 |
1.03 |
1.04 |
1.04 |
1.01 |
1.03 |
1.01 |
|
Grb2 |  |
NM_008163 |
growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] |
KLA | .92 |
.88 |
.90 |
1.27 |
1.43 |
1.22 |
1.00 |
| ATP | 1.02 |
.83 |
.51 |
.42 |
.92 |
.70 |
.57 |
| KLA/ATP | .84 |
.77 |
.61 |
.56 |
1.56 |
1.49 |
.52 |
|
Grb2 |  |
U07617 |
Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] |
KLA | .83 |
.80 |
.95 |
1.13 |
1.38 |
1.36 |
1.06 |
| ATP | .84 |
.74 |
.51 |
.41 |
.82 |
.74 |
.59 |
| KLA/ATP | .77 |
.70 |
.57 |
.54 |
1.49 |
1.39 |
.53 |
|
Gsk3b |  |
NM_019827 |
glycogen synthase kinase 3 beta (Gsk3b), mRNA [NM_019827] |
KLA | 1.06 |
1.03 |
1.11 |
1.01 |
1.26 |
1.28 |
1.26 |
| ATP | 1.18 |
1.27 |
1.15 |
2.07 |
2.37 |
2.32 |
1.67 |
| KLA/ATP | 1.15 |
1.21 |
.98 |
1.50 |
1.67 |
2.50 |
2.99 |
|
Gys1 |  |
NM_030678 |
glycogen synthase 1, muscle (Gys1), mRNA [NM_030678] |
KLA | .89 |
.89 |
.88 |
.80 |
.91 |
1.07 |
1.78 |
| ATP | 1.02 |
1.15 |
.91 |
1.01 |
.72 |
.73 |
1.14 |
| KLA/ATP | .96 |
.94 |
.73 |
.87 |
.63 |
.64 |
1.24 |
|
Gys2 |  |
NM_145572 |
glycogen synthase 2 (Gys2), mRNA [NM_145572] |
KLA | 1.01 |
.96 |
.99 |
1.06 |
1.02 |
1.00 |
.92 |
| ATP | .99 |
.98 |
.98 |
1.02 |
.95 |
1.12 |
1.10 |
| KLA/ATP | 1.03 |
.97 |
1.00 |
1.03 |
1.01 |
1.05 |
1.09 |
|
Hgf |  |
AK033274 |
15 days embryo male testis cDNA, RIKEN full-length enriched library, clone:8030481P22 product:inferred: hepatocyte growth factor [AK033274] |
KLA | 1.34 |
1.22 |
.96 |
.93 |
.82 |
.93 |
.87 |
| ATP | 1.64 |
2.45 |
3.30 |
1.89 |
.97 |
1.12 |
.90 |
| KLA/ATP | 1.49 |
2.50 |
3.96 |
1.88 |
1.07 |
1.00 |
.83 |
|
Hgf |  |
NM_010427 |
hepatocyte growth factor (Hgf), mRNA [NM_010427] |
KLA | 1.11 |
1.18 |
1.30 |
1.20 |
1.08 |
.96 |
1.14 |
| ATP | 1.02 |
1.14 |
1.32 |
1.62 |
1.17 |
1.26 |
1.47 |
| KLA/ATP | 1.18 |
1.24 |
1.33 |
1.84 |
1.19 |
1.09 |
1.31 |
|
Hras1 |  |
NM_008284 |
Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] |
KLA | .79 |
.82 |
.77 |
.82 |
.94 |
1.03 |
1.07 |
| ATP | 1.01 |
.95 |
.69 |
.83 |
.79 |
1.12 |
1.15 |
| KLA/ATP | .84 |
.77 |
.61 |
.65 |
.82 |
1.00 |
1.05 |
|
Hsp90aa1
|  |
NM_010480 |
heat shock protein 90, alpha (cytosolic), class A member 1 (Hsp90aa1), mRNA [NM_010480] |
KLA | .95 |
1.03 |
.90 |
.92 |
.80 |
.94 |
.99 |
| ATP | .96 |
.92 |
1.39 |
1.21 |
2.02 |
3.66 |
1.10 |
| KLA/ATP | .93 |
.92 |
1.32 |
1.01 |
1.85 |
2.21 |
1.20 |
|
Hsp90ab1
|  |
NM_008302 |
heat shock protein 90kDa alpha (cytosolic), class B member 1 (Hsp90ab1), mRNA [NM_008302] |
KLA | .93 |
1.02 |
.98 |
.82 |
.95 |
1.10 |
1.39 |
| ATP | 1.04 |
1.14 |
.92 |
1.32 |
1.19 |
1.02 |
.63 |
| KLA/ATP | 1.02 |
1.04 |
.80 |
1.12 |
.87 |
.86 |
.75 |
|
Hsp90b1 |  |
NM_011631 |
heat shock protein 90, beta (Grp94), member 1 (Hsp90b1), mRNA [NM_011631] |
KLA | .78 |
.83 |
.71 |
.69 |
.73 |
.69 |
.80 |
| ATP | 1.00 |
1.08 |
1.01 |
.94 |
.84 |
.84 |
.66 |
| KLA/ATP | .78 |
.82 |
.81 |
.73 |
.66 |
.68 |
.27 |
|
Ibsp |  |
NM_008318 |
integrin binding sialoprotein (Ibsp), mRNA [NM_008318] |
KLA | .99 |
1.02 |
1.05 |
.96 |
.98 |
.96 |
.97 |
| ATP | .98 |
.99 |
.99 |
.96 |
1.00 |
1.02 |
1.00 |
| KLA/ATP | 1.01 |
1.07 |
1.03 |
.93 |
.93 |
.95 |
.95 |
|
Ifna12 |  |
NM_177361 |
interferon alpha 12 (Ifna12), mRNA [NM_177361] |
KLA | 1.25 |
1.26 |
1.34 |
1.16 |
1.06 |
1.10 |
1.09 |
| ATP | 1.01 |
.97 |
1.07 |
1.09 |
1.17 |
1.20 |
1.07 |
| KLA/ATP | 1.12 |
1.29 |
1.72 |
1.54 |
1.59 |
1.56 |
1.05 |
|
Ifna13 |  |
NM_177347 |
interferon alpha 13 (Ifna13), mRNA [NM_177347] |
KLA | 1.32 |
1.27 |
1.26 |
1.34 |
1.15 |
1.24 |
1.20 |
| ATP | .95 |
1.08 |
1.29 |
1.79 |
1.41 |
1.22 |
1.08 |
| KLA/ATP | 1.36 |
1.35 |
2.04 |
2.81 |
2.07 |
1.44 |
1.19 |
|
Ifna2 |  |
K01411 |
gb|Mouse alpha-interferon (MuIFN-alpha), 3 cds & untranslated mRNA [K01411] |
KLA | 1.02 |
1.03 |
1.10 |
.96 |
.93 |
.99 |
1.01 |
| ATP | 1.02 |
.98 |
1.00 |
.98 |
1.02 |
.97 |
.95 |
| KLA/ATP | 1.02 |
1.04 |
1.18 |
1.08 |
1.13 |
1.04 |
1.01 |
|
Ifna2 |  |
NM_010503 |
interferon alpha 2 (Ifna2), mRNA [NM_010503] |
KLA | 1.08 |
1.06 |
1.07 |
1.06 |
.98 |
1.02 |
1.05 |
| ATP | .94 |
1.06 |
1.11 |
1.30 |
1.24 |
1.25 |
1.21 |
| KLA/ATP | 1.03 |
1.20 |
1.19 |
1.35 |
1.52 |
1.60 |
1.18 |
|
Ifna4 |  |
NM_010504 |
interferon alpha 4 (Ifna4), mRNA [NM_010504] |
KLA | .99 |
1.04 |
1.05 |
.97 |
1.00 |
.96 |
.99 |
| ATP | 1.01 |
.96 |
.98 |
1.01 |
1.00 |
1.00 |
.97 |
| KLA/ATP | 1.10 |
1.09 |
1.05 |
1.04 |
1.01 |
.97 |
1.01 |
|
Ifna5 |  |
NM_010505 |
interferon alpha 5 (Ifna5), mRNA [NM_010505] |
KLA | 1.15 |
1.23 |
1.51 |
1.26 |
1.03 |
1.06 |
1.05 |
| ATP | .99 |
.94 |
1.11 |
1.00 |
1.09 |
1.07 |
1.03 |
| KLA/ATP | 1.12 |
1.29 |
1.46 |
1.47 |
1.24 |
1.32 |
1.03 |
|
Ifna9 |  |
NM_010507 |
interferon alpha 9 (Ifna9), mRNA [NM_010507] |
KLA | 1.05 |
1.09 |
1.20 |
1.06 |
1.08 |
1.06 |
1.02 |
| ATP | .99 |
1.08 |
1.18 |
1.21 |
1.09 |
.99 |
.97 |
| KLA/ATP | 1.09 |
1.23 |
1.19 |
1.24 |
1.18 |
1.16 |
1.04 |
|
Ifnab |  |
BC116864 |
interferon alpha B, mRNA (cDNA clone MGC:151241 IMAGE:40126183), complete cds [BC116864] |
KLA | 1.20 |
1.33 |
1.29 |
1.30 |
1.20 |
1.20 |
1.08 |
| ATP | .99 |
.99 |
1.00 |
1.25 |
1.13 |
1.19 |
1.04 |
| KLA/ATP | 1.30 |
1.39 |
1.44 |
1.48 |
1.49 |
1.54 |
1.22 |
|
Ifnar1 |  |
NM_010508 |
interferon (alpha and beta) receptor 1 (Ifnar1), mRNA [NM_010508] |
KLA | 1.35 |
1.29 |
1.19 |
1.39 |
1.60 |
1.47 |
1.49 |
| ATP | 1.18 |
1.25 |
.94 |
1.06 |
1.07 |
1.48 |
1.52 |
| KLA/ATP | 1.56 |
1.57 |
.98 |
1.43 |
1.08 |
1.79 |
3.54 |
|
Ifnar2 |  |
NM_010509 |
interferon (alpha and beta) receptor 2 (Ifnar2), transcript variant 1, mRNA [NM_010509] |
KLA | 1.45 |
1.43 |
1.67 |
1.87 |
2.31 |
1.84 |
1.36 |
| ATP | .99 |
.92 |
.87 |
1.03 |
1.38 |
1.79 |
1.43 |
| KLA/ATP | 1.48 |
1.48 |
1.24 |
1.54 |
1.77 |
2.10 |
2.81 |
|
Ifnb1 |  |
NM_010510 |
interferon beta 1, fibroblast (Ifnb1), mRNA [NM_010510] |
KLA | 49.82 |
46.57 |
34.05 |
16.05 |
5.94 |
7.31 |
8.49 |
| ATP | .99 |
1.02 |
1.89 |
4.78 |
6.31 |
4.44 |
1.79 |
| KLA/ATP | 49.22 |
61.83 |
134.08 |
144.05 |
110.96 |
31.78 |
11.24 |
|
Igf1 |  |
AK050118 |
adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730016P09 product:unclassifiable, full insert sequence. [AK050118] |
KLA | .13 |
.14 |
.15 |
.16 |
.22 |
.34 |
.48 |
| ATP | 1.78 |
2.05 |
1.37 |
.72 |
.34 |
.41 |
.58 |
| KLA/ATP | .24 |
.45 |
.50 |
.24 |
.20 |
.26 |
.68 |
|
Igf1 |  |
NM_010512 |
insulin-like growth factor 1 (Igf1), transcript variant 1, mRNA [NM_010512] |
KLA | .84 |
.78 |
.76 |
.67 |
.54 |
.48 |
.59 |
| ATP | .97 |
.98 |
1.13 |
1.13 |
1.03 |
.88 |
.89 |
| KLA/ATP | .82 |
.81 |
.93 |
.86 |
.83 |
.65 |
.89 |
|
Igf1 |  |
NM_184052 |
insulin-like growth factor 1 (Igf1), transcript variant 2, mRNA [NM_184052] |
KLA | .77 |
.82 |
.76 |
.65 |
.60 |
.52 |
.69 |
| ATP | 1.01 |
1.07 |
.98 |
1.06 |
1.03 |
.78 |
.94 |
| KLA/ATP | .89 |
.86 |
.77 |
.80 |
.75 |
.65 |
.89 |
|
Igf1r |  |
NM_010513 |
insulin-like growth factor I receptor (Igf1r), mRNA [NM_010513] |
KLA | 1.32 |
1.32 |
1.08 |
.91 |
.55 |
.48 |
.45 |
| ATP | 1.03 |
1.06 |
1.06 |
1.29 |
1.31 |
1.45 |
.47 |
| KLA/ATP | 1.30 |
1.37 |
1.11 |
1.00 |
.93 |
1.02 |
.45 |
|
Igh-VJ55 8 |  |
AY547436 |
immunoglobulin heavy chain VDJ region mRNA, partial cds [AY547436] |
KLA | 1.06 |
1.05 |
1.01 |
.93 |
1.03 |
.96 |
.93 |
| ATP | .99 |
1.00 |
1.06 |
.95 |
.96 |
1.06 |
1.05 |
| KLA/ATP | .98 |
.94 |
1.07 |
.95 |
.97 |
.99 |
1.02 |
|
Igh-VJ55 8 |  |
CA578712 |
gb|K0727F04-5N NIA Mouse Hematopoietic Stem Cell (Lin- [CA578712] |
KLA | .99 |
.94 |
1.01 |
1.10 |
.93 |
.97 |
.92 |
| ATP | .93 |
1.04 |
1.01 |
.98 |
1.05 |
.96 |
.95 |
| KLA/ATP | .99 |
.95 |
.95 |
.98 |
1.02 |
.98 |
.95 |
|
Igh-VJ55 8 |  |
ENSMUST00000103412 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHA] [ENSMUST00000103412] |
KLA | 1.01 |
.97 |
1.20 |
1.01 |
.98 |
1.44 |
1.24 |
| ATP | .99 |
.98 |
1.07 |
1.03 |
1.00 |
1.01 |
1.21 |
| KLA/ATP | .99 |
1.02 |
.96 |
1.03 |
.97 |
1.13 |
1.30 |
|
Igh-VJ55 8 |  |
ENSMUST00000103413 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHE] [ENSMUST00000103413] |
KLA | 1.00 |
.99 |
1.06 |
1.06 |
.99 |
1.03 |
1.02 |
| ATP | 1.08 |
1.06 |
1.06 |
1.06 |
1.02 |
1.06 |
.95 |
| KLA/ATP | 1.00 |
1.04 |
1.09 |
1.02 |
1.06 |
1.02 |
.95 |
|
Igh-VJ55 8 |  |
U39781 |
J558+ IgM heavy chain mRNA, hybridoma clone ME2B7, partial cds. [U39781] |
KLA | .93 |
.89 |
.98 |
.97 |
1.03 |
1.00 |
.94 |
| ATP | 1.04 |
1.02 |
1.08 |
.94 |
.93 |
.90 |
.79 |
| KLA/ATP | .88 |
.89 |
.97 |
.93 |
.88 |
.92 |
.82 |
|
Ikbkb |  |
NM_010546 |
inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] |
KLA | 1.88 |
2.10 |
2.14 |
1.83 |
1.73 |
1.31 |
1.19 |
| ATP | .81 |
.74 |
.55 |
.49 |
.59 |
1.05 |
.96 |
| KLA/ATP | 1.86 |
1.73 |
1.39 |
1.12 |
.89 |
1.17 |
1.24 |
|
Ikbkg |  |
AK042138 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] |
KLA | .92 |
.87 |
.78 |
.78 |
.87 |
.88 |
.62 |
| ATP | .84 |
.71 |
.80 |
.50 |
1.15 |
2.33 |
.61 |
| KLA/ATP | .72 |
.69 |
.74 |
.48 |
1.06 |
1.97 |
.68 |
|
Ikbkg |  |
NM_010547 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] |
KLA | 1.51 |
1.63 |
1.74 |
1.83 |
1.83 |
1.73 |
1.72 |
| ATP | .80 |
.79 |
.82 |
.75 |
.66 |
2.58 |
2.37 |
| KLA/ATP | 1.43 |
1.42 |
1.17 |
1.04 |
.71 |
1.54 |
3.17 |
|
Ikbkg |  |
NM_178590 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] |
KLA | .84 |
.93 |
.86 |
.91 |
1.03 |
.89 |
.88 |
| ATP | 1.03 |
.98 |
.68 |
.56 |
.51 |
.93 |
.68 |
| KLA/ATP | .89 |
.81 |
.55 |
.52 |
.41 |
.67 |
.65 |
|
Il2 |  |
NM_008366 |
interleukin 2 (Il2), mRNA [NM_008366] |
KLA | .96 |
.97 |
.96 |
1.00 |
.97 |
.97 |
.99 |
| ATP | 1.04 |
1.02 |
1.00 |
1.03 |
.97 |
.98 |
.97 |
| KLA/ATP | 1.01 |
.98 |
.97 |
1.00 |
.97 |
.97 |
.96 |
|
Il2ra |  |
AF054581 |
interleukin 2 receptor mRNA, 3UTR, partial sequence. [AF054581] |
KLA | 1.76 |
2.05 |
2.73 |
2.46 |
3.58 |
2.68 |
1.13 |
| ATP | .99 |
.99 |
1.00 |
1.09 |
1.13 |
1.14 |
1.03 |
| KLA/ATP | 1.93 |
2.11 |
1.32 |
2.27 |
1.87 |
2.13 |
1.37 |
|
Il2ra |  |
NM_008367 |
interleukin 2 receptor, alpha chain (Il2ra), mRNA [NM_008367] |
KLA | 1.33 |
1.29 |
1.46 |
1.43 |
1.82 |
1.57 |
1.15 |
| ATP | 1.02 |
1.03 |
1.01 |
1.02 |
1.01 |
1.12 |
1.05 |
| KLA/ATP | 1.30 |
1.46 |
1.36 |
1.41 |
1.22 |
1.47 |
1.66 |
|
Il2rb |  |
NM_008368 |
interleukin 2 receptor, beta chain (Il2rb), mRNA [NM_008368] |
KLA | .92 |
1.00 |
1.00 |
1.00 |
.91 |
.98 |
1.09 |
| ATP | 1.02 |
.98 |
1.00 |
.95 |
1.02 |
1.04 |
1.04 |
| KLA/ATP | 1.03 |
.98 |
1.01 |
.99 |
.94 |
1.13 |
1.00 |
|
Il2rg |  |
NM_013563 |
interleukin 2 receptor, gamma chain (Il2rg), mRNA [NM_013563] |
KLA | 2.97 |
2.92 |
3.73 |
3.39 |
4.04 |
3.45 |
4.83 |
| ATP | 1.25 |
1.41 |
1.04 |
1.82 |
1.48 |
1.12 |
2.89 |
| KLA/ATP | 3.65 |
4.34 |
2.42 |
4.70 |
2.62 |
2.54 |
5.15 |
|
Il3 |  |
NM_010556 |
interleukin 3 (Il3), mRNA [NM_010556] |
KLA | 1.05 |
.94 |
1.01 |
.99 |
1.03 |
1.07 |
.95 |
| ATP | .95 |
1.03 |
1.03 |
.98 |
.98 |
.97 |
.96 |
| KLA/ATP | 1.02 |
1.03 |
1.02 |
.94 |
.97 |
1.02 |
1.04 |
|
Il3ra |  |
NM_008369 |
interleukin 3 receptor, alpha chain (Il3ra), mRNA [NM_008369] |
KLA | 1.23 |
1.35 |
1.52 |
1.31 |
1.38 |
1.42 |
1.35 |
| ATP | 1.04 |
1.20 |
1.11 |
1.42 |
1.18 |
.94 |
.77 |
| KLA/ATP | 1.33 |
1.45 |
1.45 |
1.69 |
1.25 |
1.22 |
1.32 |
|
Il4 |  |
NM_021283 |
interleukin 4 (Il4), mRNA [NM_021283] |
KLA | .94 |
.95 |
.91 |
.94 |
.91 |
.94 |
1.07 |
| ATP | 1.02 |
1.06 |
1.05 |
1.22 |
1.12 |
1.10 |
1.26 |
| KLA/ATP | .92 |
.96 |
.93 |
1.08 |
.98 |
1.03 |
1.18 |
|
Il4ra |  |
NM_001008700 |
interleukin 4 receptor, alpha (Il4ra), mRNA [NM_001008700] |
KLA | 4.65 |
4.81 |
8.69 |
11.26 |
14.81 |
9.10 |
1.64 |
| ATP | .97 |
.88 |
.64 |
.58 |
3.81 |
9.28 |
4.93 |
| KLA/ATP | 4.86 |
4.84 |
5.43 |
3.60 |
4.37 |
10.35 |
6.16 |
|
Il6 |  |
NM_031168 |
interleukin 6 (Il6), mRNA [NM_031168] |
KLA | 352.99 |
378.70 |
276.81 |
168.47 |
59.99 |
18.66 |
8.27 |
| ATP | 1.04 |
1.08 |
2.28 |
3.69 |
30.40 |
161.93 |
2.11 |
| KLA/ATP | 334.28 |
528.66 |
###.## |
935.86 |
302.45 |
355.36 |
99.65 |
|
Il6ra |  |
NM_010559 |
interleukin 6 receptor, alpha (Il6ra), mRNA [NM_010559] |
KLA | .50 |
.53 |
.65 |
.86 |
1.36 |
1.72 |
1.00 |
| ATP | .97 |
1.20 |
1.17 |
1.25 |
.74 |
.67 |
.95 |
| KLA/ATP | .50 |
.60 |
.61 |
.64 |
.59 |
.76 |
1.14 |
|
Il7 |  |
AK041403 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630007F02 product:interleukin 7, full insert sequence [AK041403] |
KLA | .96 |
.96 |
.97 |
1.00 |
1.01 |
.97 |
1.08 |
| ATP | 1.05 |
1.00 |
.98 |
.99 |
.94 |
.98 |
.95 |
| KLA/ATP | 1.05 |
1.05 |
.96 |
.99 |
.94 |
.99 |
.92 |
|
Il7 |  |
NM_008371 |
interleukin 7 (Il7), mRNA [NM_008371] |
KLA | 1.29 |
1.38 |
1.32 |
1.39 |
1.24 |
1.40 |
1.26 |
| ATP | 1.01 |
.98 |
1.02 |
.98 |
1.03 |
1.10 |
1.08 |
| KLA/ATP | 1.22 |
1.31 |
1.17 |
1.20 |
1.04 |
1.21 |
1.32 |
|
Il7r |  |
AK041838 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630041A17 product:interleukin 7 receptor, full insert sequence. [AK041838] |
KLA | .90 |
1.04 |
.92 |
.95 |
.90 |
1.05 |
.99 |
| ATP | .97 |
1.01 |
1.11 |
1.04 |
1.06 |
1.33 |
2.92 |
| KLA/ATP | .98 |
.97 |
.91 |
1.10 |
1.06 |
1.20 |
1.57 |
|
Il7r |  |
NM_008372 |
interleukin 7 receptor (Il7r), mRNA [NM_008372] |
KLA | .42 |
.40 |
.37 |
.41 |
.36 |
.60 |
.73 |
| ATP | 1.02 |
1.01 |
1.23 |
1.13 |
1.72 |
2.94 |
7.90 |
| KLA/ATP | .40 |
.41 |
.53 |
.58 |
1.00 |
2.18 |
4.13 |
|
Ins1 |  |
NM_008386 |
insulin I (Ins1), mRNA [NM_008386] |
KLA | 1.00 |
.99 |
.99 |
1.03 |
1.01 |
.98 |
1.06 |
| ATP | .97 |
1.03 |
1.00 |
1.03 |
.99 |
1.07 |
1.05 |
| KLA/ATP | 1.03 |
.93 |
.98 |
1.04 |
1.07 |
1.03 |
1.01 |
|
Ins2 |  |
NM_008387 |
insulin II (Ins2), mRNA [NM_008387] |
KLA | .99 |
1.00 |
1.00 |
1.01 |
1.00 |
1.02 |
1.00 |
| ATP | 1.01 |
.99 |
1.00 |
1.00 |
.98 |
.99 |
1.01 |
| KLA/ATP | .99 |
1.01 |
1.00 |
.98 |
.99 |
.99 |
.98 |
|
Insr |  |
NM_010568 |
insulin receptor (Insr), mRNA [NM_010568] |
KLA | .75 |
.81 |
.77 |
.69 |
.69 |
.69 |
.83 |
| ATP | 1.07 |
1.06 |
.88 |
.79 |
.73 |
.77 |
.83 |
| KLA/ATP | .80 |
.80 |
.72 |
.71 |
.64 |
.64 |
.70 |
|
Irs1 |  |
NM_010570 |
insulin receptor substrate 1 (Irs1), mRNA [NM_010570] |
KLA | .97 |
.96 |
.99 |
1.01 |
.93 |
.94 |
.94 |
| ATP | 1.00 |
.99 |
1.02 |
.96 |
.96 |
.94 |
.91 |
| KLA/ATP | .96 |
.96 |
.98 |
.96 |
.97 |
.98 |
.92 |
|
Itga1 |  |
NM_001033228 |
integrin alpha 1 (Itga1), mRNA [NM_001033228] |
KLA | 1.08 |
1.09 |
1.13 |
1.05 |
1.04 |
.99 |
1.01 |
| ATP | 1.02 |
.97 |
1.03 |
1.03 |
1.09 |
1.43 |
3.50 |
| KLA/ATP | 1.06 |
1.04 |
1.07 |
1.00 |
1.06 |
1.12 |
1.33 |
|
Itga10 |  |
NM_001081053 |
integrin, alpha 10 (Itga10), mRNA [NM_001081053] |
KLA | .98 |
1.00 |
1.00 |
1.04 |
1.04 |
.96 |
1.00 |
| ATP | 1.05 |
1.00 |
.97 |
.98 |
.95 |
.96 |
.97 |
| KLA/ATP | 1.04 |
.98 |
.92 |
.96 |
.95 |
.97 |
1.00 |
|
Itga11 |  |
NM_176922 |
integrin, alpha 11 (Itga11), mRNA [NM_176922] |
KLA | .95 |
.92 |
.90 |
.97 |
.93 |
.93 |
.96 |
| ATP | .97 |
.92 |
.98 |
.95 |
.90 |
.94 |
.95 |
| KLA/ATP | .86 |
.94 |
1.01 |
.93 |
.97 |
.94 |
.88 |
|
Itga2 |  |
NM_008396 |
integrin alpha 2 (Itga2), mRNA [NM_008396] |
KLA | 1.03 |
1.00 |
.98 |
1.01 |
.97 |
.96 |
1.00 |
| ATP | 1.05 |
.99 |
.93 |
1.02 |
1.04 |
1.03 |
.97 |
| KLA/ATP | .98 |
1.06 |
1.03 |
1.00 |
1.00 |
1.01 |
1.01 |
|
Itga2b |  |
NM_010575 |
integrin alpha 2b (Itga2b), mRNA [NM_010575] |
KLA | 1.01 |
1.00 |
.98 |
1.04 |
1.01 |
1.04 |
1.18 |
| ATP | 1.01 |
.98 |
.95 |
1.02 |
.96 |
1.13 |
1.08 |
| KLA/ATP | 1.04 |
1.02 |
1.02 |
.95 |
1.05 |
1.53 |
1.23 |
|
Itga3 |  |
NM_013565 |
integrin alpha 3 (Itga3), mRNA [NM_013565] |
KLA | 1.06 |
1.09 |
1.10 |
1.17 |
1.19 |
1.29 |
1.41 |
| ATP | .99 |
.99 |
1.05 |
1.12 |
1.20 |
1.25 |
1.33 |
| KLA/ATP | 1.08 |
1.14 |
1.15 |
1.27 |
1.28 |
1.20 |
1.39 |
|
Itga4 |  |
NM_010576 |
integrin alpha 4 (Itga4), mRNA [NM_010576] |
KLA | 4.65 |
4.83 |
4.47 |
3.76 |
2.93 |
1.65 |
1.01 |
| ATP | 1.10 |
1.12 |
1.17 |
1.08 |
.86 |
.75 |
.36 |
| KLA/ATP | 4.82 |
5.02 |
4.43 |
3.69 |
2.11 |
1.13 |
.79 |
|
Itga5 |  |
NM_010577 |
integrin alpha 5 (fibronectin receptor alpha) (Itga5), mRNA [NM_010577] |
KLA | 2.63 |
3.04 |
2.81 |
2.47 |
4.61 |
5.45 |
4.90 |
| ATP | 1.13 |
1.62 |
.74 |
2.21 |
1.31 |
1.93 |
2.84 |
| KLA/ATP | 3.55 |
3.84 |
1.15 |
3.03 |
1.11 |
2.81 |
10.42 |
|
Itga6 |  |
BC024571 |
integrin alpha 6, mRNA (cDNA clone IMAGE:5036677). [BC024571] |
KLA | .44 |
.44 |
.37 |
.28 |
.25 |
.29 |
.34 |
| ATP | .96 |
1.01 |
.90 |
.58 |
.35 |
.11 |
.22 |
| KLA/ATP | .44 |
.41 |
.34 |
.23 |
.15 |
.09 |
.08 |
|
Itga6 |  |
NM_008397 |
integrin alpha 6 (Itga6), mRNA [NM_008397] |
KLA | .57 |
.58 |
.51 |
.45 |
.43 |
.44 |
.47 |
| ATP | 1.05 |
1.12 |
.86 |
.90 |
.57 |
.27 |
.36 |
| KLA/ATP | .64 |
.67 |
.50 |
.57 |
.39 |
.29 |
.26 |
|
Itga7 |  |
L23423 |
gb|Mouse (BALB/c) alpha-7 integrin mRNA, complete cds. [L23423] |
KLA | .96 |
1.03 |
1.00 |
1.07 |
1.02 |
1.07 |
1.14 |
| ATP | 1.00 |
1.00 |
1.04 |
1.88 |
2.09 |
1.34 |
1.16 |
| KLA/ATP | 1.04 |
.97 |
1.07 |
1.79 |
1.68 |
1.39 |
1.11 |
|
Itga7 |  |
NM_008398 |
integrin alpha 7 (Itga7), mRNA [NM_008398] |
KLA | .98 |
.95 |
.98 |
1.01 |
1.04 |
1.03 |
.98 |
| ATP | 1.00 |
1.02 |
1.06 |
1.75 |
1.92 |
1.20 |
1.02 |
| KLA/ATP | 1.03 |
1.07 |
1.06 |
1.48 |
1.58 |
1.23 |
1.05 |
|
Itga8 |  |
NM_001001309 |
integrin alpha 8 (Itga8), mRNA [NM_001001309] |
KLA | .80 |
.81 |
.79 |
.75 |
.63 |
.61 |
.44 |
| ATP | .98 |
1.04 |
1.06 |
.94 |
.79 |
.61 |
.50 |
| KLA/ATP | .79 |
.81 |
.81 |
.71 |
.70 |
.65 |
.48 |
|
Itgav |  |
AK052514 |
13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430040G12 product:hypothetical protein, full insert sequence. [AK052514] |
KLA | 1.04 |
.93 |
1.05 |
1.02 |
1.01 |
.93 |
1.03 |
| ATP | 1.05 |
1.04 |
1.13 |
1.12 |
1.12 |
.91 |
1.02 |
| KLA/ATP | 1.08 |
.97 |
1.02 |
.95 |
1.01 |
.96 |
1.05 |
|
Itgav |  |
AK171739 |
activated spleen cDNA, RIKEN full-length enriched library, clone:F830008B15 product:unclassifiable, full insert sequence. [AK171739] |
KLA | 1.04 |
.97 |
1.06 |
.95 |
1.15 |
.89 |
1.11 |
| ATP | 1.41 |
1.54 |
1.64 |
2.24 |
2.74 |
1.24 |
1.18 |
| KLA/ATP | 1.09 |
1.07 |
1.03 |
1.01 |
1.72 |
1.24 |
1.10 |
|
Itgav |  |
NM_008402 |
integrin alpha V (Itgav), mRNA [NM_008402] |
KLA | 4.00 |
3.99 |
3.28 |
2.24 |
1.57 |
.95 |
1.13 |
| ATP | 1.14 |
1.22 |
1.13 |
1.39 |
2.22 |
2.47 |
1.70 |
| KLA/ATP | 4.59 |
4.61 |
2.48 |
2.44 |
1.60 |
1.88 |
2.56 |
|
Itgb1 |  |
NM_010578 |
integrin beta 1 (fibronectin receptor beta) (Itgb1), mRNA [NM_010578] |
KLA | 1.05 |
1.09 |
1.13 |
.92 |
1.01 |
.93 |
.88 |
| ATP | 1.14 |
1.30 |
.92 |
1.07 |
1.04 |
.83 |
.70 |
| KLA/ATP | 1.26 |
1.30 |
.87 |
1.02 |
.66 |
.65 |
.62 |
|
Itgb1 |  |
U37029 |
integrin beta1D mRNA, partial cds. [U37029] |
KLA | .93 |
.95 |
.96 |
1.01 |
.97 |
1.01 |
.98 |
| ATP | 1.05 |
.99 |
.99 |
1.03 |
1.03 |
.97 |
.94 |
| KLA/ATP | .99 |
.98 |
1.04 |
.97 |
1.02 |
1.01 |
.99 |
|
Itgb3 |  |
AF026509 |
integrin beta3 subunit mRNA, complete cds. [AF026509] |
KLA | 2.38 |
2.64 |
2.65 |
3.15 |
4.02 |
4.46 |
2.83 |
| ATP | 1.21 |
1.17 |
1.25 |
1.62 |
2.33 |
3.09 |
4.78 |
| KLA/ATP | 2.48 |
2.63 |
3.39 |
3.72 |
4.30 |
4.71 |
6.79 |
|
Itgb3 |  |
NM_016780 |
integrin beta 3 (Itgb3), mRNA [NM_016780] |
KLA | .50 |
.51 |
.52 |
.41 |
.31 |
.25 |
.15 |
| ATP | .94 |
.88 |
1.17 |
.89 |
.99 |
1.36 |
.91 |
| KLA/ATP | .51 |
.54 |
.67 |
.52 |
.61 |
.74 |
.48 |
|
Itgb4 |  |
AK048888 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230078O20 product:integrin beta 4, full insert sequence. [AK048888] |
KLA | .98 |
.92 |
.98 |
1.08 |
.97 |
1.02 |
1.02 |
| ATP | .99 |
.99 |
.91 |
1.03 |
1.02 |
1.00 |
1.05 |
| KLA/ATP | .99 |
1.03 |
.99 |
.98 |
.94 |
.98 |
1.01 |
|
Itgb4 |  |
NM_001005608 |
integrin beta 4 (Itgb4), transcript variant 1, mRNA [NM_001005608] |
KLA | 1.09 |
1.11 |
1.12 |
1.08 |
.98 |
.86 |
.85 |
| ATP | .90 |
.89 |
.90 |
.95 |
.87 |
.87 |
.84 |
| KLA/ATP | 1.06 |
1.08 |
1.10 |
1.18 |
1.07 |
.90 |
.76 |
|
Itgb5 |  |
NM_010580 |
integrin beta 5 (Itgb5), mRNA [NM_010580] |
KLA | .72 |
.68 |
.67 |
.66 |
.54 |
.43 |
.36 |
| ATP | 1.09 |
.94 |
.78 |
.57 |
.63 |
.56 |
.62 |
| KLA/ATP | .78 |
.64 |
.67 |
.51 |
.64 |
.67 |
.38 |
|
Itgb6 |  |
NM_021359 |
integrin beta 6 (Itgb6), mRNA [NM_021359] |
KLA | .97 |
1.02 |
1.04 |
1.06 |
1.06 |
1.04 |
1.01 |
| ATP | .99 |
1.00 |
1.01 |
.96 |
1.04 |
1.00 |
1.00 |
| KLA/ATP | .99 |
1.03 |
1.08 |
1.02 |
1.02 |
1.03 |
1.01 |
|
Itgb7 |  |
NM_013566 |
integrin beta 7 (Itgb7), mRNA [NM_013566] |
KLA | .91 |
.88 |
.93 |
1.19 |
.93 |
.76 |
.79 |
| ATP | 1.00 |
.96 |
1.30 |
1.44 |
2.84 |
3.07 |
7.90 |
| KLA/ATP | .96 |
1.05 |
1.35 |
1.20 |
2.70 |
3.53 |
8.17 |
|
Itgb8 |  |
AK029281 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4832412O06 product:SIMILAR TO INTEGRIN, BETA 8 homolog [Homo sapiens], full insert sequence. [AK029281] |
KLA | 4.66 |
5.00 |
3.59 |
2.70 |
1.76 |
1.34 |
1.32 |
| ATP | 1.01 |
.98 |
1.09 |
1.16 |
2.15 |
5.24 |
1.17 |
| KLA/ATP | 5.59 |
6.39 |
4.38 |
1.99 |
1.84 |
2.55 |
2.11 |
|
Itgb8 |  |
AK034644 |
12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430018C17 product:integrin beta 8, full insert sequence. [AK034644] |
KLA | 1.18 |
1.02 |
1.04 |
1.03 |
1.05 |
.94 |
.93 |
| ATP | .96 |
.97 |
.97 |
.96 |
.90 |
1.04 |
.99 |
| KLA/ATP | 1.06 |
1.06 |
1.15 |
.92 |
.99 |
1.00 |
1.09 |
|
Itgb8 |  |
AK140969 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130086L01 product:hypothetical protein, full insert sequence [AK140969] |
KLA | 3.63 |
3.76 |
4.16 |
3.31 |
2.72 |
1.58 |
1.40 |
| ATP | .98 |
1.01 |
1.31 |
1.14 |
1.28 |
6.11 |
1.65 |
| KLA/ATP | 3.84 |
4.18 |
3.75 |
2.83 |
1.92 |
3.44 |
4.81 |
|
Jak1 |  |
AK029232 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4831433J01 product:Janus kinase 1, full insert sequence. [AK029232] |
KLA | 1.25 |
1.13 |
1.19 |
1.31 |
1.24 |
1.17 |
1.14 |
| ATP | 1.01 |
1.11 |
.96 |
1.38 |
1.06 |
1.26 |
1.05 |
| KLA/ATP | 1.19 |
1.29 |
1.27 |
1.59 |
1.18 |
1.38 |
1.24 |
|
Jak1 |  |
NM_146145 |
Janus kinase 1 (Jak1), mRNA [NM_146145] |
KLA | 1.71 |
1.75 |
1.79 |
1.81 |
1.72 |
1.37 |
1.21 |
| ATP | 1.03 |
1.01 |
.75 |
1.04 |
1.32 |
1.90 |
1.14 |
| KLA/ATP | 1.84 |
1.73 |
1.49 |
2.07 |
2.01 |
1.83 |
1.68 |
|
Jak2 |  |
NM_008413 |
Janus kinase 2 (Jak2), transcript variant 1, mRNA [NM_008413] |
KLA | 14.86 |
15.05 |
15.42 |
14.15 |
11.46 |
8.81 |
5.47 |
| ATP | .99 |
1.06 |
1.09 |
1.43 |
2.83 |
4.71 |
1.62 |
| KLA/ATP | 13.77 |
14.74 |
14.94 |
12.97 |
7.53 |
9.34 |
9.17 |
|
Jak3 |  |
NM_010589 |
Janus kinase 3 (Jak3), mRNA [NM_010589] |
KLA | 1.46 |
1.56 |
1.79 |
1.62 |
2.05 |
1.72 |
1.65 |
| ATP | 1.11 |
1.19 |
.84 |
1.25 |
.82 |
.61 |
.71 |
| KLA/ATP | 1.76 |
1.82 |
1.10 |
1.74 |
.93 |
.83 |
1.01 |
|
Kdr |  |
AK054510 |
2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330034B14 product:kinase insert domain protein receptor, full insert sequence. [AK054510] |
KLA | 1.00 |
1.00 |
.98 |
1.03 |
1.02 |
1.00 |
.99 |
| ATP | .99 |
1.00 |
1.00 |
1.02 |
1.00 |
1.00 |
1.00 |
| KLA/ATP | 1.01 |
1.02 |
1.03 |
1.02 |
.98 |
1.00 |
1.01 |
|
Kdr |  |
NM_010612 |
kinase insert domain protein receptor (Kdr), mRNA [NM_010612] |
KLA | 7.30 |
7.28 |
6.48 |
6.79 |
5.97 |
6.18 |
2.71 |
| ATP | 1.00 |
.84 |
1.06 |
1.14 |
3.62 |
3.10 |
7.15 |
| KLA/ATP | 6.62 |
7.17 |
7.12 |
6.48 |
14.11 |
12.63 |
11.01 |
|
Kit |  |
Y00864 |
gb|Mouse c-kit mRNA. [Y00864] |
KLA | .88 |
.86 |
.83 |
.76 |
.75 |
.73 |
.87 |
| ATP | 1.06 |
1.07 |
1.03 |
1.04 |
3.95 |
1.93 |
1.25 |
| KLA/ATP | .87 |
.87 |
.89 |
.89 |
1.06 |
1.08 |
.91 |
|
Kitl |  |
NM_013598 |
kit ligand (Kitl), mRNA [NM_013598] |
KLA | .49 |
.46 |
.43 |
.38 |
.23 |
.35 |
.46 |
| ATP | .89 |
.85 |
.79 |
.91 |
1.14 |
1.30 |
.86 |
| KLA/ATP | .48 |
.43 |
.49 |
.96 |
1.59 |
1.38 |
.95 |
|
Klk1b4 |  |
NM_010915 |
kallikrein 1-related pepidase b4 (Klk1b4), mRNA [NM_010915] |
KLA | 1.07 |
1.10 |
1.07 |
1.02 |
1.06 |
.95 |
1.04 |
| ATP | .94 |
1.05 |
1.03 |
.97 |
.94 |
1.07 |
1.10 |
| KLA/ATP | .96 |
.97 |
1.13 |
1.09 |
.99 |
.99 |
.99 |
|
Kras |  |
NM_021284 |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] |
KLA | .53 |
.49 |
.40 |
.42 |
.49 |
.95 |
1.05 |
| ATP | .98 |
1.01 |
1.16 |
1.17 |
1.39 |
1.29 |
1.74 |
| KLA/ATP | .50 |
.47 |
.50 |
.56 |
1.00 |
1.24 |
1.58 |
|
Lama1 |  |
NM_008480 |
laminin, alpha 1 (Lama1), mRNA [NM_008480] |
KLA | .99 |
1.04 |
.97 |
.96 |
1.01 |
.99 |
1.05 |
| ATP | 1.01 |
.99 |
.98 |
1.05 |
.99 |
1.09 |
.99 |
| KLA/ATP | 1.00 |
.97 |
.86 |
1.04 |
1.05 |
.99 |
1.00 |
|
Lama2 |  |
AK046114 |
adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230342M05 product:laminin, alpha 2, full insert sequence. [AK046114] |
KLA | 1.06 |
1.00 |
.95 |
1.10 |
1.04 |
.99 |
.96 |
| ATP | .98 |
1.09 |
1.00 |
.97 |
.96 |
1.12 |
1.01 |
| KLA/ATP | .94 |
1.04 |
1.05 |
1.00 |
.99 |
1.00 |
.98 |
|
Lama2 |  |
NM_008481 |
laminin, alpha 2 (Lama2), mRNA [NM_008481] |
KLA | .96 |
.99 |
.96 |
1.02 |
.95 |
1.00 |
.97 |
| ATP | 1.05 |
1.00 |
1.01 |
.94 |
1.01 |
1.04 |
.96 |
| KLA/ATP | .99 |
1.04 |
1.06 |
1.10 |
.98 |
.95 |
.97 |
|
Lama2 |  |
U12147 |
laminin-2 alpha2 chain mRNA, complete cds. [U12147] |
KLA | .96 |
1.00 |
.99 |
1.00 |
.98 |
1.02 |
1.03 |
| ATP | 1.01 |
.99 |
1.02 |
1.04 |
1.01 |
.99 |
1.02 |
| KLA/ATP | 1.00 |
1.01 |
1.00 |
1.01 |
.99 |
1.04 |
1.00 |
|
Lama3 |  |
XM_140451 |
gb|PREDICTED: Mus musculus laminin, alpha 3, transcript variant 1 (Lama3), mRNA [XM_140451] |
KLA | .76 |
.75 |
.73 |
.75 |
.71 |
.74 |
.67 |
| ATP | 1.04 |
1.12 |
1.05 |
1.20 |
.88 |
.73 |
.78 |
| KLA/ATP | .77 |
.81 |
.78 |
.82 |
.78 |
.71 |
.70 |
|
Lama4 |  |
NM_010681 |
laminin, alpha 4 (Lama4), mRNA [NM_010681] |
KLA | .99 |
.99 |
1.01 |
1.02 |
.98 |
.97 |
.96 |
| ATP | 1.00 |
1.08 |
1.05 |
1.05 |
1.03 |
1.04 |
.96 |
| KLA/ATP | 1.00 |
1.03 |
.93 |
1.00 |
.94 |
.90 |
.95 |
|
Lama5 |  |
NM_001081171 |
laminin, alpha 5 (Lama5), mRNA [NM_001081171] |
KLA | 1.11 |
1.07 |
1.09 |
1.00 |
.96 |
1.00 |
1.01 |
| ATP | 1.01 |
.99 |
1.03 |
1.01 |
1.00 |
.99 |
.99 |
| KLA/ATP | 1.12 |
1.08 |
1.05 |
1.04 |
.99 |
1.09 |
1.04 |
|
Lamb1-1 |  |
NM_008482 |
laminin B1 subunit 1 (Lamb1-1), mRNA [NM_008482] |
KLA | .93 |
.99 |
1.10 |
1.01 |
.95 |
1.00 |
.86 |
| ATP | .99 |
1.13 |
1.06 |
.99 |
1.07 |
.99 |
.97 |
| KLA/ATP | 1.00 |
1.06 |
.98 |
.95 |
.93 |
.89 |
1.04 |
|
Lamb2 |  |
NM_008483 |
laminin, beta 2 (Lamb2), mRNA [NM_008483] |
KLA | .93 |
.90 |
.95 |
.81 |
.79 |
.58 |
.37 |
| ATP | 1.01 |
1.09 |
.95 |
.99 |
.80 |
.81 |
.38 |
| KLA/ATP | .96 |
.87 |
1.00 |
.91 |
.72 |
.60 |
.38 |
|
Lamb3 |  |
NM_008484 |
laminin, beta 3 (Lamb3), mRNA [NM_008484] |
KLA | 1.00 |
.97 |
1.02 |
.98 |
1.00 |
1.04 |
.93 |
| ATP | 1.01 |
1.01 |
.91 |
.97 |
.89 |
1.04 |
1.03 |
| KLA/ATP | 1.00 |
.95 |
.97 |
1.00 |
.95 |
.87 |
1.02 |
|
Lamc1 |  |
J03484 |
gb|Mouse laminin B2 chain mRNA, complete cds [J03484] |
KLA | 1.14 |
1.01 |
1.04 |
.87 |
.82 |
.63 |
.75 |
| ATP | .99 |
1.09 |
1.07 |
1.14 |
1.36 |
2.38 |
.66 |
| KLA/ATP | 1.04 |
1.10 |
.95 |
1.12 |
1.30 |
1.70 |
.68 |
|
Lamc2 |  |
AF106279 |
laminin gamma2 chain mRNA, partial cds. [AF106279] |
KLA | 1.03 |
1.04 |
1.03 |
1.09 |
.97 |
.97 |
.98 |
| ATP | 1.04 |
1.04 |
1.16 |
1.48 |
1.46 |
1.29 |
1.26 |
| KLA/ATP | 1.04 |
1.00 |
1.03 |
1.06 |
.95 |
.99 |
1.08 |
|
Lamc2 |  |
NM_008485 |
laminin, gamma 2 (Lamc2), mRNA [NM_008485] |
KLA | 1.16 |
1.22 |
1.23 |
1.07 |
1.04 |
1.12 |
1.04 |
| ATP | 1.01 |
1.10 |
2.81 |
4.58 |
4.35 |
3.34 |
2.36 |
| KLA/ATP | 1.31 |
1.29 |
1.41 |
1.40 |
1.28 |
1.25 |
1.49 |
|
Lamc3 |  |
AF083372 |
laminin 12 gamma 3 chain mRNA, complete cds. [AF083372] |
KLA | .96 |
.94 |
.99 |
.96 |
.94 |
1.02 |
.88 |
| ATP | 1.06 |
1.00 |
.95 |
.98 |
.98 |
.99 |
1.02 |
| KLA/ATP | .90 |
.98 |
1.03 |
.95 |
.88 |
.97 |
.96 |
|
Lamc3 |  |
NM_011836 |
laminin gamma 3 (Lamc3), mRNA [NM_011836] |
KLA | 1.00 |
1.00 |
1.04 |
1.04 |
1.03 |
1.01 |
.97 |
| ATP | .99 |
1.06 |
1.00 |
.91 |
.98 |
.96 |
1.01 |
| KLA/ATP | .98 |
1.04 |
1.01 |
1.02 |
.96 |
.95 |
.98 |
|
Lpar2 |  |
NM_020028 |
lysophosphatidic acid receptor 2 (Lpar2), mRNA [NM_020028] |
KLA | .80 |
.84 |
.81 |
.80 |
.72 |
.71 |
.78 |
| ATP | 1.08 |
1.02 |
1.00 |
1.14 |
1.02 |
.82 |
.75 |
| KLA/ATP | .98 |
.82 |
.87 |
.81 |
1.06 |
.76 |
.69 |
|
Lpar3 |  |
NM_022983 |
lysophosphatidic acid receptor 3 (Lpar3), mRNA [NM_022983] |
KLA | 1.04 |
1.04 |
1.09 |
1.01 |
.96 |
.96 |
.97 |
| ATP | .98 |
.97 |
.94 |
1.07 |
1.06 |
1.04 |
.98 |
| KLA/ATP | 1.05 |
1.14 |
1.02 |
1.06 |
1.24 |
1.06 |
1.01 |
|
Lpar4 |  |
NM_175271 |
lysophosphatidic acid receptor 4 (Lpar4), mRNA [NM_175271] |
KLA | 1.15 |
1.14 |
1.12 |
1.07 |
.98 |
1.00 |
1.04 |
| ATP | 1.06 |
1.00 |
1.07 |
.98 |
.94 |
.99 |
.94 |
| KLA/ATP | 1.15 |
1.17 |
1.14 |
1.13 |
1.05 |
1.08 |
1.01 |
|
Lpar5 |  |
XM_355812 |
gb|PREDICTED: Mus musculus G protein-coupled receptor 92 (Gpr92), mRNA [XM_355812] |
KLA | 1.15 |
1.19 |
1.13 |
1.20 |
1.00 |
1.13 |
1.05 |
| ATP | .99 |
1.06 |
1.08 |
1.03 |
.84 |
1.00 |
.99 |
| KLA/ATP | 1.11 |
1.24 |
1.26 |
1.17 |
1.16 |
.98 |
.98 |
|
Map2k1 |  |
NM_008927 |
mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] |
KLA | 1.82 |
2.00 |
2.31 |
2.03 |
2.51 |
2.20 |
1.51 |
| ATP | .99 |
1.14 |
.81 |
.87 |
.90 |
1.57 |
1.11 |
| KLA/ATP | 1.90 |
2.03 |
1.50 |
1.93 |
1.63 |
2.03 |
2.06 |
|
Map2k2 |  |
NM_023138 |
mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] |
KLA | .96 |
1.01 |
1.09 |
.99 |
1.11 |
1.15 |
1.42 |
| ATP | 1.07 |
1.05 |
.74 |
.86 |
1.04 |
1.16 |
1.21 |
| KLA/ATP | 1.14 |
1.03 |
.68 |
.78 |
.85 |
1.01 |
1.20 |
|
Mapk1 |  |
NM_001038663 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] |
KLA | .97 |
1.03 |
.93 |
.86 |
.79 |
1.01 |
1.04 |
| ATP | .96 |
1.18 |
1.01 |
1.13 |
.84 |
1.04 |
1.16 |
| KLA/ATP | .99 |
.99 |
.84 |
.87 |
.63 |
.96 |
1.26 |
|
Mapk1 |  |
NM_011949 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] |
KLA | .88 |
.80 |
.80 |
.73 |
.75 |
.76 |
.65 |
| ATP | .97 |
.96 |
1.06 |
.88 |
.90 |
.68 |
.48 |
| KLA/ATP | .82 |
.81 |
.78 |
.65 |
.64 |
.64 |
.45 |
|
Mapk3 |  |
NM_011952 |
mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] |
KLA | .81 |
.85 |
.88 |
.72 |
.79 |
.73 |
.90 |
| ATP | 1.13 |
1.30 |
.92 |
1.48 |
1.08 |
.68 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
.66 |
1.13 |
.77 |
.77 |
1.16 |
|
Mcl1 |  |
NM_008562 |
myeloid cell leukemia sequence 1 (Mcl1), mRNA [NM_008562] |
KLA | 1.08 |
1.07 |
1.20 |
1.31 |
1.66 |
1.91 |
2.02 |
| ATP | 1.13 |
1.19 |
.82 |
.84 |
1.60 |
1.74 |
2.17 |
| KLA/ATP | 1.09 |
1.18 |
.81 |
.90 |
1.75 |
2.48 |
3.72 |
|
Mdm2 |  |
NM_010786 |
transformed mouse 3T3 cell double minute 2 (Mdm2), mRNA [NM_010786] |
KLA | 1.77 |
1.59 |
1.98 |
1.51 |
1.77 |
1.60 |
1.77 |
| ATP | 1.01 |
1.21 |
1.36 |
3.24 |
5.04 |
2.08 |
1.36 |
| KLA/ATP | 1.89 |
1.86 |
2.93 |
5.65 |
5.98 |
2.78 |
2.64 |
|
Met |  |
NM_008591 |
met proto-oncogene (Met), mRNA [NM_008591] |
KLA | 3.56 |
3.71 |
3.68 |
3.79 |
4.24 |
5.89 |
6.95 |
| ATP | .98 |
.96 |
1.16 |
1.21 |
3.32 |
12.98 |
6.60 |
| KLA/ATP | 3.75 |
3.80 |
3.58 |
3.28 |
3.69 |
4.27 |
14.22 |
|
Mm.19309 9 |  |
46849811 |
Unknown |
KLA | 1.32 |
1.36 |
1.42 |
1.17 |
1.06 |
.90 |
.58 |
| ATP | .98 |
1.12 |
1.41 |
1.81 |
1.44 |
1.14 |
.89 |
| KLA/ATP | 1.39 |
1.55 |
1.57 |
2.02 |
1.43 |
1.12 |
.74 |
|
Mm.21312 8 |  |
141801344 |
Unknown |
KLA | .96 |
.95 |
.83 |
.77 |
.52 |
.99 |
1.32 |
| ATP | .80 |
.82 |
1.09 |
.80 |
.83 |
1.19 |
1.46 |
| KLA/ATP | .78 |
.92 |
.98 |
.62 |
.71 |
.94 |
1.41 |
|
Mm.24060 7 |  |
162951825 |
Unknown |
KLA | .94 |
.96 |
.91 |
1.02 |
.90 |
.84 |
.97 |
| ATP | 1.08 |
1.01 |
1.08 |
.95 |
1.04 |
.89 |
.89 |
| KLA/ATP | .93 |
1.01 |
1.05 |
.92 |
.84 |
.88 |
.76 |
|
Mm.25381 9 |  |
118130676 |
Unknown |
KLA | 1.81 |
1.88 |
1.96 |
1.62 |
1.89 |
2.44 |
1.56 |
| ATP | .92 |
.91 |
1.24 |
1.01 |
1.16 |
2.06 |
1.95 |
| KLA/ATP | 1.62 |
1.86 |
1.86 |
1.41 |
1.89 |
2.37 |
1.97 |
|
Mm.25806 5 |  |
148747407 |
Unknown |
KLA | 1.05 |
1.02 |
1.03 |
1.00 |
.99 |
1.05 |
.94 |
| ATP | .98 |
.98 |
1.03 |
1.02 |
.99 |
1.06 |
1.03 |
| KLA/ATP | 1.01 |
1.02 |
1.03 |
1.01 |
.96 |
.98 |
1.01 |
|
Mm.27304 9 |  |
119672895 |
Unknown |
KLA | .23 |
.22 |
.22 |
.22 |
.30 |
.51 |
.16 |
| ATP | 1.08 |
1.05 |
.88 |
.78 |
.47 |
.09 |
.20 |
| KLA/ATP | .28 |
.22 |
.21 |
.24 |
.26 |
.22 |
.12 |
|
Mm.27574 2 |  |
112983655 |
Unknown |
KLA | 1.35 |
1.16 |
.94 |
.85 |
.45 |
.33 |
.31 |
| ATP | .90 |
.86 |
1.17 |
1.09 |
1.18 |
1.21 |
.38 |
| KLA/ATP | 1.12 |
1.22 |
1.19 |
.91 |
.90 |
.83 |
.33 |
|
Mm.29002 2 |  |
167234371 |
Unknown |
KLA | .53 |
.50 |
.44 |
.38 |
.36 |
.39 |
.57 |
| ATP | 1.01 |
1.07 |
1.01 |
1.02 |
.84 |
.42 |
.40 |
| KLA/ATP | .53 |
.51 |
.38 |
.41 |
.47 |
.40 |
.21 |
|
Mm.33981 2 |  |
6679780 |
Unknown |
KLA | 1.10 |
1.14 |
1.09 |
1.05 |
1.05 |
1.08 |
1.01 |
| ATP | .95 |
1.06 |
2.35 |
11.15 |
2.46 |
1.50 |
1.03 |
| KLA/ATP | 1.02 |
1.05 |
2.05 |
8.78 |
2.65 |
1.76 |
1.02 |
|
Mm.37708 7 |  |
158631169 |
Unknown |
KLA | .98 |
.98 |
1.06 |
1.06 |
.91 |
.97 |
1.04 |
| ATP | 1.00 |
1.07 |
1.01 |
1.06 |
1.09 |
.99 |
1.02 |
| KLA/ATP | 1.08 |
1.06 |
1.16 |
1.11 |
1.16 |
1.12 |
1.04 |
|
Mm.38049
|  |
118130391 |
Unknown |
KLA | .67 |
.65 |
.73 |
.92 |
.63 |
.81 |
.76 |
| ATP | .93 |
.92 |
1.08 |
.54 |
.45 |
1.48 |
1.56 |
| KLA/ATP | .57 |
.65 |
.98 |
.67 |
.44 |
.78 |
1.16 |
|
Mm.42523 6 |  |
117320553 |
Unknown |
KLA | .98 |
.98 |
1.03 |
1.00 |
.99 |
1.02 |
1.02 |
| ATP | 1.01 |
.99 |
1.03 |
1.02 |
1.05 |
.94 |
.96 |
| KLA/ATP | 1.08 |
1.04 |
1.06 |
1.01 |
1.00 |
1.01 |
1.05 |
|
Mm.42730 7 |  |
109809755 |
Unknown |
KLA | 1.07 |
1.13 |
.97 |
1.03 |
1.01 |
.96 |
1.09 |
| ATP | 1.01 |
1.02 |
.92 |
.94 |
.72 |
.73 |
.87 |
| KLA/ATP | 1.08 |
1.13 |
.93 |
.89 |
.85 |
.79 |
.70 |
|
Mm.4387 |  |
133892666 |
Unknown |
KLA | .85 |
.87 |
.85 |
.89 |
.77 |
.91 |
1.18 |
| ATP | 1.01 |
1.01 |
.87 |
1.07 |
.75 |
.86 |
.93 |
| KLA/ATP | .88 |
.86 |
.77 |
.81 |
.72 |
.91 |
.84 |
|
Mm.44050 5 |  |
84579905 |
Unknown |
KLA | 1.03 |
.96 |
.90 |
1.03 |
.94 |
1.15 |
1.23 |
| ATP | .88 |
.91 |
1.15 |
1.18 |
1.17 |
1.31 |
1.02 |
| KLA/ATP | .87 |
.97 |
1.19 |
1.18 |
1.36 |
1.34 |
1.25 |
|
Mm.46042 5 |  |
145699103 |
Unknown |
KLA | .97 |
1.06 |
1.00 |
1.00 |
1.04 |
1.00 |
1.06 |
| ATP | .98 |
1.03 |
.96 |
.96 |
1.00 |
1.05 |
.96 |
| KLA/ATP | .99 |
.95 |
1.04 |
.97 |
1.01 |
.98 |
.93 |
|
Mm.47351 0 |  |
162287332 |
Unknown |
KLA | 4.46 |
4.82 |
5.29 |
4.00 |
2.26 |
1.25 |
1.10 |
| ATP | 1.24 |
1.72 |
1.02 |
2.08 |
1.66 |
2.53 |
.55 |
| KLA/ATP | 6.11 |
7.67 |
4.29 |
6.99 |
3.11 |
2.86 |
2.30 |
|
Mm.47445 5 |  |
149260531 |
Unknown |
KLA | .99 |
.93 |
.95 |
.92 |
.97 |
.92 |
.95 |
| ATP | .99 |
1.13 |
1.08 |
1.23 |
1.05 |
.94 |
.86 |
| KLA/ATP | 1.02 |
.95 |
.89 |
1.15 |
1.02 |
.94 |
.83 |
|
Mm.4987 |  |
160358832 |
Unknown |
KLA | 1.04 |
1.02 |
1.05 |
1.00 |
1.06 |
1.02 |
1.00 |
| ATP | 1.11 |
1.00 |
1.08 |
1.01 |
1.05 |
1.09 |
1.04 |
| KLA/ATP | 1.08 |
1.05 |
.94 |
1.04 |
1.06 |
1.11 |
.99 |
|
Mm.5055 |  |
145966820 |
Unknown |
KLA | 1.04 |
.96 |
1.04 |
.97 |
1.00 |
1.00 |
.97 |
| ATP | .95 |
.97 |
.96 |
.95 |
.97 |
.97 |
.98 |
| KLA/ATP | .88 |
1.04 |
1.07 |
1.02 |
.97 |
.98 |
.96 |
|
Mm.57127
|  |
117168292 |
Unknown |
KLA | 1.20 |
1.25 |
1.28 |
1.18 |
1.14 |
1.13 |
1.12 |
| ATP | .98 |
.95 |
1.11 |
1.06 |
1.05 |
1.05 |
1.09 |
| KLA/ATP | 1.22 |
1.24 |
1.48 |
1.55 |
1.40 |
1.21 |
1.07 |
|
Mtcp1 |  |
NM_001039373 |
mature T-cell proliferation 1 (Mtcp1), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA [NM_001039373] |
KLA | 1.14 |
1.17 |
1.35 |
1.31 |
1.25 |
1.32 |
1.29 |
| ATP | .96 |
1.04 |
.97 |
.93 |
.78 |
.81 |
.93 |
| KLA/ATP | 1.22 |
1.17 |
1.21 |
1.18 |
1.12 |
1.11 |
1.11 |
|
Mtcp1 |  |
NM_010839 |
mature T-cell proliferation 1 (Mtcp1), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA [NM_010839] |
KLA | 1.31 |
1.30 |
1.48 |
1.43 |
1.35 |
1.51 |
1.36 |
| ATP | .84 |
.80 |
.95 |
1.00 |
.89 |
.82 |
.68 |
| KLA/ATP | 1.06 |
.97 |
1.07 |
1.31 |
1.70 |
1.46 |
1.49 |
|
Myb |  |
AK036518 |
adult male bone cDNA, RIKEN full-length enriched library, clone:9830125P17 product:myeloblastosis oncogene, full insert sequence. [AK036518] |
KLA | 1.02 |
.96 |
1.03 |
1.00 |
.96 |
1.07 |
.99 |
| ATP | 1.07 |
.96 |
1.03 |
.99 |
.96 |
1.03 |
1.00 |
| KLA/ATP | 1.04 |
1.07 |
.83 |
.93 |
1.06 |
1.03 |
1.00 |
|
Myb |  |
M16449 |
gb|Mouse myb mRNA, complete cds [M16449] |
KLA | .97 |
1.07 |
1.09 |
1.01 |
1.01 |
1.02 |
.98 |
| ATP | 1.06 |
.98 |
1.05 |
1.06 |
.91 |
.91 |
.84 |
| KLA/ATP | 1.08 |
1.07 |
.80 |
1.03 |
1.01 |
.92 |
.90 |
|
Myb |  |
NM_010848 |
myeloblastosis oncogene (Myb), mRNA [NM_010848] |
KLA | 1.07 |
1.05 |
1.11 |
1.09 |
1.06 |
.99 |
.91 |
| ATP | .99 |
1.05 |
1.05 |
.95 |
.94 |
.93 |
.82 |
| KLA/ATP | 1.04 |
1.09 |
1.07 |
.97 |
.94 |
.95 |
.82 |
|
Myc |  |
NM_010849 |
myelocytomatosis oncogene (Myc), mRNA [NM_010849] |
KLA | .38 |
.31 |
.45 |
.45 |
.49 |
.35 |
.33 |
| ATP | 1.05 |
1.09 |
1.72 |
4.41 |
1.28 |
.45 |
.76 |
| KLA/ATP | .37 |
.30 |
.44 |
1.23 |
.34 |
.17 |
.19 |
|
Nfkb1 |  |
BC050841 |
nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] |
KLA | 5.81 |
4.96 |
4.77 |
3.21 |
3.37 |
2.00 |
1.71 |
| ATP | 1.39 |
1.52 |
3.25 |
12.63 |
13.64 |
4.80 |
1.08 |
| KLA/ATP | 7.21 |
8.69 |
19.53 |
23.93 |
11.70 |
2.85 |
2.01 |
|
Nfkb1 |  |
M57999 |
gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] |
KLA | 8.55 |
7.87 |
7.35 |
6.13 |
3.51 |
1.85 |
1.38 |
| ATP | .98 |
.96 |
1.21 |
3.06 |
5.29 |
4.67 |
.69 |
| KLA/ATP | 7.32 |
7.20 |
8.71 |
10.82 |
5.55 |
2.77 |
1.54 |
|
Ngf |  |
NM_013609 |
nerve growth factor (Ngf), transcript variant A, mRNA [NM_013609] |
KLA | .99 |
.98 |
.97 |
.99 |
.97 |
1.10 |
1.05 |
| ATP | .94 |
1.03 |
.99 |
1.00 |
.93 |
1.05 |
1.01 |
| KLA/ATP | .94 |
1.01 |
.99 |
.98 |
.98 |
1.11 |
1.02 |
|
Ngfr |  |
NM_033217 |
nerve growth factor receptor (TNFR superfamily, member 16) (Ngfr), mRNA [NM_033217] |
KLA | 1.06 |
1.08 |
1.08 |
1.06 |
1.07 |
1.09 |
1.08 |
| ATP | .99 |
1.01 |
1.06 |
1.03 |
1.01 |
1.04 |
1.04 |
| KLA/ATP | 1.04 |
1.07 |
1.08 |
1.06 |
1.05 |
1.04 |
1.11 |
|
Nos3 |  |
NM_008713 |
nitric oxide synthase 3, endothelial cell (Nos3), mRNA [NM_008713] |
KLA | .83 |
.79 |
.76 |
.78 |
.77 |
.85 |
.96 |
| ATP | 1.03 |
1.09 |
1.03 |
1.02 |
.85 |
.96 |
1.84 |
| KLA/ATP | .80 |
.78 |
.79 |
.80 |
.79 |
.78 |
.91 |
|
Nr4a1 |  |
NM_010444 |
nuclear receptor subfamily 4, group A, member 1 (Nr4a1), mRNA [NM_010444] |
KLA | .44 |
.45 |
.47 |
.82 |
.71 |
.50 |
.55 |
| ATP | 11.54 |
20.34 |
46.57 |
49.45 |
32.16 |
7.11 |
.84 |
| KLA/ATP | 4.55 |
17.35 |
51.68 |
56.03 |
42.95 |
13.43 |
2.21 |
|
Nras |  |
NM_010937 |
neuroblastoma ras oncogene (Nras), mRNA [NM_010937] |
KLA | 1.20 |
1.22 |
1.27 |
1.20 |
1.09 |
.91 |
.84 |
| ATP | .98 |
.91 |
.69 |
.61 |
.59 |
.67 |
.78 |
| KLA/ATP | 1.22 |
1.14 |
.97 |
.79 |
.73 |
.61 |
.72 |
|
Osm |  |
NM_001013365 |
oncostatin M (Osm), mRNA [NM_001013365] |
KLA | 1.56 |
1.46 |
1.46 |
2.02 |
1.99 |
1.68 |
1.47 |
| ATP | 2.40 |
4.29 |
10.76 |
14.66 |
10.66 |
9.53 |
2.21 |
| KLA/ATP | 1.94 |
3.15 |
10.63 |
13.85 |
12.20 |
11.12 |
5.30 |
|
Osmr |  |
NM_011019 |
oncostatin M receptor (Osmr), mRNA [NM_011019] |
KLA | 1.18 |
1.26 |
1.23 |
1.16 |
1.13 |
1.08 |
1.03 |
| ATP | 1.02 |
1.00 |
1.04 |
1.04 |
1.10 |
1.07 |
1.04 |
| KLA/ATP | 1.21 |
1.17 |
1.17 |
1.14 |
1.19 |
1.10 |
1.08 |
|
P2ry5 |  |
NM_175116 |
purinergic receptor P2Y, G-protein coupled, 5 (P2ry5), mRNA [NM_175116] |
KLA | .16 |
.17 |
.21 |
.19 |
.20 |
.33 |
.28 |
| ATP | 1.25 |
1.44 |
1.75 |
1.01 |
.54 |
1.08 |
.90 |
| KLA/ATP | .17 |
.17 |
.26 |
.27 |
.35 |
.49 |
.57 |
|
Pck2 |  |
NM_028994 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) (Pck2), nuclear gene encoding mitochondrial protein, mRNA [NM_028994] |
KLA | .40 |
.37 |
.32 |
.28 |
.37 |
.56 |
.55 |
| ATP | .99 |
.96 |
.86 |
.94 |
1.02 |
.57 |
.77 |
| KLA/ATP | .40 |
.37 |
.31 |
.35 |
.42 |
.35 |
.46 |
|
Pdgfa |  |
NM_008808 |
platelet derived growth factor, alpha (Pdgfa), mRNA [NM_008808] |
KLA | .63 |
.56 |
.42 |
.34 |
.31 |
.33 |
.52 |
| ATP | .89 |
.80 |
.69 |
1.23 |
5.97 |
3.99 |
2.73 |
| KLA/ATP | .64 |
.53 |
.43 |
.77 |
3.48 |
3.78 |
2.37 |
|
Pdgfb |  |
NM_011057 |
platelet derived growth factor, B polypeptide (Pdgfb), mRNA [NM_011057] |
KLA | .45 |
.43 |
.38 |
.46 |
.69 |
.48 |
.58 |
| ATP | .94 |
.95 |
.66 |
.74 |
.67 |
.77 |
1.06 |
| KLA/ATP | .43 |
.43 |
.37 |
.39 |
.52 |
.55 |
1.64 |
|
Pdgfc |  |
AK081347 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130008P20 product:platelet-derived growth factor, C polypeptide, full insert sequence. [AK081347] |
KLA | .93 |
1.07 |
1.00 |
1.03 |
.93 |
.95 |
.98 |
| ATP | 1.05 |
1.04 |
.94 |
1.02 |
1.04 |
1.00 |
1.05 |
| KLA/ATP | 1.06 |
1.02 |
.99 |
.96 |
.99 |
1.05 |
1.01 |
|
Pdgfc |  |
NM_019971 |
platelet-derived growth factor, C polypeptide (Pdgfc), mRNA [NM_019971] |
KLA | 1.56 |
1.52 |
1.84 |
2.08 |
1.83 |
1.33 |
.79 |
| ATP | .98 |
.91 |
.86 |
.91 |
.78 |
1.43 |
3.28 |
| KLA/ATP | 1.45 |
1.50 |
1.25 |
1.73 |
1.99 |
1.56 |
1.12 |
|
Pdgfd |  |
AK141551 |
adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630020I23 product:platelet-derived growth factor, D polypeptide, full insert sequence [AK141551] |
KLA | 1.07 |
1.01 |
1.06 |
.98 |
.94 |
1.00 |
1.00 |
| ATP | .98 |
.99 |
1.10 |
1.00 |
.96 |
1.00 |
.94 |
| KLA/ATP | 1.00 |
1.03 |
1.05 |
1.02 |
.94 |
.97 |
1.03 |
|
Pdgfd |  |
NM_027924 |
platelet-derived growth factor, D polypeptide (Pdgfd), mRNA [NM_027924] |
KLA | .99 |
.93 |
.95 |
.97 |
1.00 |
.99 |
.95 |
| ATP | 1.01 |
.99 |
1.00 |
.93 |
1.05 |
1.04 |
1.06 |
| KLA/ATP | .91 |
.91 |
.96 |
.92 |
.92 |
.99 |
1.05 |
|
Pdgfra |  |
NM_011058 |
platelet derived growth factor receptor, alpha polypeptide (Pdgfra), transcript variant 1, mRNA [NM_011058] |
KLA | 1.02 |
1.05 |
1.02 |
1.01 |
1.03 |
1.03 |
1.01 |
| ATP | 1.01 |
1.02 |
1.03 |
1.04 |
1.00 |
1.01 |
1.01 |
| KLA/ATP | 1.01 |
1.01 |
.99 |
1.03 |
1.02 |
1.03 |
1.01 |
|
Pdgfrb |  |
NM_008809 |
platelet derived growth factor receptor, beta polypeptide (Pdgfrb), mRNA [NM_008809] |
KLA | 4.85 |
5.49 |
4.56 |
3.94 |
3.71 |
2.05 |
1.51 |
| ATP | .99 |
1.00 |
1.11 |
1.27 |
1.02 |
1.83 |
1.23 |
| KLA/ATP | 5.09 |
5.86 |
4.30 |
2.51 |
1.74 |
1.84 |
3.23 |
|
Pdpk1 |  |
NM_011062 |
3-phosphoinositide dependent protein kinase-1 (Pdpk1), transcript variant 1, mRNA [NM_011062] |
KLA | .90 |
.90 |
.84 |
1.00 |
1.32 |
1.19 |
1.15 |
| ATP | 1.05 |
1.09 |
1.04 |
1.14 |
1.31 |
.97 |
1.17 |
| KLA/ATP | .90 |
.89 |
.91 |
1.02 |
1.27 |
.96 |
1.42 |
|
Pgf |  |
NM_008827 |
placental growth factor (Pgf), mRNA [NM_008827] |
KLA | 1.59 |
1.43 |
1.58 |
1.66 |
1.51 |
1.67 |
1.19 |
| ATP | .94 |
1.05 |
1.49 |
3.36 |
5.65 |
4.56 |
3.89 |
| KLA/ATP | 1.64 |
1.61 |
1.95 |
2.17 |
3.19 |
4.33 |
4.95 |
|
Phlpp |  |
XM_129968 |
gb|PREDICTED: Mus musculus PH domain and leucine rich repeat protein phosphatase, transcript variant 1 (Phlpp), mRNA [XM_129968] |
KLA | 4.22 |
4.69 |
7.54 |
5.41 |
3.09 |
2.10 |
2.09 |
| ATP | 1.09 |
1.23 |
1.03 |
2.83 |
3.71 |
2.88 |
1.35 |
| KLA/ATP | 4.68 |
5.42 |
4.74 |
10.16 |
10.52 |
8.94 |
4.30 |
|
Phlppl |  |
NM_001122594 |
PH domain and leucine rich repeat protein phosphatase-like (Phlppl), mRNA [NM_001122594] |
KLA | 1.93 |
1.82 |
1.81 |
1.66 |
1.16 |
1.23 |
.98 |
| ATP | .98 |
.95 |
1.25 |
.98 |
1.47 |
1.70 |
.88 |
| KLA/ATP | 1.76 |
1.78 |
2.15 |
1.54 |
3.12 |
2.24 |
1.08 |
|
Pik3ap1 |  |
AK171021 |
NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F630218N05 product:phosphoinositide-3-kinase adaptor protein 1, full insert sequence [AK171021] |
KLA | 1.50 |
1.68 |
2.02 |
1.89 |
2.34 |
2.36 |
2.67 |
| ATP | 1.08 |
1.14 |
.70 |
.73 |
.70 |
.68 |
2.56 |
| KLA/ATP | 1.78 |
1.63 |
.94 |
1.38 |
.94 |
1.40 |
3.40 |
|
Pik3ap1 |  |
NM_031376 |
phosphoinositide-3-kinase adaptor protein 1 (Pik3ap1), mRNA [NM_031376] |
KLA | 1.95 |
1.92 |
2.40 |
2.59 |
3.05 |
2.56 |
2.75 |
| ATP | 1.18 |
1.21 |
.79 |
1.07 |
.98 |
1.00 |
2.68 |
| KLA/ATP | 2.18 |
2.33 |
1.85 |
2.35 |
1.31 |
1.87 |
4.82 |
|
Pik3ca |  |
ENSMUST00000108243 |
ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] |
KLA | 1.07 |
1.01 |
.91 |
.90 |
.98 |
.96 |
.86 |
| ATP | 1.03 |
.87 |
1.12 |
.63 |
1.22 |
1.86 |
.60 |
| KLA/ATP | 1.05 |
.82 |
.91 |
.61 |
1.17 |
1.26 |
.63 |
|
Pik3ca |  |
NM_008839 |
phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] |
KLA | 1.15 |
1.11 |
1.05 |
.82 |
.99 |
1.03 |
1.27 |
| ATP | .98 |
1.00 |
.79 |
.75 |
.96 |
1.32 |
1.10 |
| KLA/ATP | 1.10 |
.98 |
.64 |
.72 |
.80 |
1.20 |
1.41 |
|
Pik3cb |  |
NM_029094 |
phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] |
KLA | 1.06 |
1.06 |
1.03 |
.73 |
.68 |
.98 |
1.69 |
| ATP | 1.04 |
1.21 |
.95 |
1.02 |
.85 |
.93 |
1.73 |
| KLA/ATP | 1.15 |
1.27 |
.73 |
.83 |
.58 |
.81 |
1.81 |
|
Pik3cd |  |
NM_008840 |
phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] |
KLA | 2.28 |
2.42 |
3.10 |
4.17 |
3.35 |
2.31 |
1.34 |
| ATP | 1.02 |
.91 |
.99 |
.63 |
.30 |
.67 |
.80 |
| KLA/ATP | 2.14 |
2.23 |
2.70 |
1.51 |
1.17 |
.85 |
.72 |
|
Pik3cd |  |
U86587 |
phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] |
KLA | 2.21 |
2.24 |
3.71 |
3.17 |
3.67 |
2.66 |
1.48 |
| ATP | 1.00 |
1.03 |
.93 |
.96 |
.46 |
.75 |
.97 |
| KLA/ATP | 2.27 |
2.32 |
1.97 |
2.02 |
1.01 |
.99 |
.98 |
|
Pik3cg |  |
NM_020272 |
phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] |
KLA | .53 |
.53 |
.61 |
.64 |
.97 |
.86 |
.79 |
| ATP | 1.01 |
1.13 |
.88 |
.89 |
.52 |
.53 |
.53 |
| KLA/ATP | .58 |
.53 |
.43 |
.60 |
.40 |
.43 |
.62 |
|
Pik3r1 |  |
NM_001077495 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] |
KLA | 1.05 |
1.07 |
1.03 |
1.00 |
1.01 |
1.20 |
.85 |
| ATP | .97 |
1.02 |
1.48 |
1.42 |
1.76 |
1.33 |
1.23 |
| KLA/ATP | 1.11 |
1.12 |
1.06 |
1.17 |
1.24 |
.99 |
1.12 |
|
Pik3r2 |  |
NM_008841 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] |
KLA | .50 |
.50 |
.48 |
.43 |
.46 |
.66 |
.75 |
| ATP | .78 |
.68 |
.45 |
.43 |
.28 |
.57 |
1.37 |
| KLA/ATP | .49 |
.38 |
.32 |
.33 |
.38 |
.67 |
1.10 |
|
Pik3r3 |  |
NM_181585 |
phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] |
KLA | 1.59 |
1.49 |
1.37 |
1.17 |
1.05 |
1.55 |
1.41 |
| ATP | 1.12 |
1.00 |
1.33 |
1.70 |
2.01 |
2.37 |
2.02 |
| KLA/ATP | 1.63 |
1.54 |
1.58 |
1.70 |
2.43 |
2.68 |
1.92 |
|
Pik3r5 |  |
NM_177320 |
phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] |
KLA | 3.57 |
3.58 |
4.16 |
3.54 |
4.11 |
2.59 |
2.39 |
| ATP | 1.08 |
1.08 |
.93 |
1.67 |
3.11 |
1.88 |
1.34 |
| KLA/ATP | 3.91 |
3.70 |
3.30 |
3.80 |
2.70 |
2.04 |
3.00 |
|
Pkn1 |  |
NM_177262 |
protein kinase N1 (Pkn1), mRNA [NM_177262] |
KLA | 1.00 |
1.05 |
1.21 |
1.17 |
1.81 |
2.23 |
1.45 |
| ATP | 1.04 |
1.08 |
.91 |
1.07 |
.93 |
1.41 |
2.42 |
| KLA/ATP | 1.09 |
1.06 |
.93 |
1.08 |
.91 |
1.73 |
3.64 |
|
Pkn2 |  |
AK140746 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130001L23 product:protein kinase N2, full insert sequence [AK140746] |
KLA | 2.11 |
2.12 |
2.30 |
1.86 |
1.65 |
1.52 |
1.45 |
| ATP | 1.03 |
1.09 |
.93 |
.96 |
1.69 |
1.26 |
1.10 |
| KLA/ATP | 2.12 |
2.03 |
1.58 |
1.65 |
1.92 |
1.41 |
1.37 |
|
Pkn2 |  |
NM_178654 |
protein kinase N2 (Pkn2), mRNA [NM_178654] |
KLA | 1.99 |
2.05 |
2.24 |
2.09 |
1.67 |
1.69 |
1.57 |
| ATP | 1.05 |
1.11 |
1.29 |
1.36 |
2.32 |
2.68 |
1.55 |
| KLA/ATP | 2.03 |
2.15 |
2.31 |
2.32 |
3.12 |
2.89 |
2.30 |
|
Pkn3 |  |
AK154801 |
NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F630107C11 product:protein kinase N3, full insert sequence [AK154801] |
KLA | 2.16 |
2.25 |
2.92 |
2.78 |
3.14 |
3.90 |
2.74 |
| ATP | 1.08 |
1.03 |
1.18 |
1.20 |
1.18 |
1.59 |
3.46 |
| KLA/ATP | 2.36 |
2.41 |
2.70 |
2.63 |
2.44 |
3.39 |
7.83 |
|
Pkn3 |  |
NM_153805 |
protein kinase N3 (Pkn3), mRNA [NM_153805] |
KLA | .82 |
.78 |
.76 |
.76 |
.73 |
.73 |
.68 |
| ATP | .96 |
1.06 |
1.04 |
1.01 |
.81 |
1.03 |
.78 |
| KLA/ATP | .84 |
.77 |
.81 |
.77 |
.76 |
.89 |
.76 |
|
Ppp2ca |  |
NM_019411 |
protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform (Ppp2ca), mRNA [NM_019411] |
KLA | 1.17 |
1.13 |
1.18 |
1.20 |
1.54 |
1.45 |
1.34 |
| ATP | 1.09 |
1.20 |
1.07 |
1.33 |
1.56 |
2.04 |
1.43 |
| KLA/ATP | 1.14 |
1.17 |
1.15 |
1.49 |
1.59 |
2.37 |
2.02 |
|
Ppp2cb |  |
NM_017374 |
protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform (Ppp2cb), mRNA [NM_017374] |
KLA | 1.32 |
1.33 |
1.37 |
1.24 |
1.27 |
1.09 |
1.18 |
| ATP | .94 |
.93 |
.82 |
.91 |
1.22 |
2.01 |
1.08 |
| KLA/ATP | 1.24 |
1.14 |
.80 |
.97 |
1.13 |
1.54 |
1.18 |
|
Ppp2r1a |  |
NM_016891 |
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform (Ppp2r1a), mRNA [NM_016891] |
KLA | 1.44 |
1.39 |
1.47 |
1.37 |
1.69 |
1.33 |
1.16 |
| ATP | 1.18 |
1.55 |
.85 |
1.67 |
1.38 |
.99 |
1.24 |
| KLA/ATP | 1.66 |
1.98 |
.97 |
2.33 |
1.41 |
1.65 |
1.38 |
|
Ppp2r1b |  |
NM_001034085 |
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform (Ppp2r1b), transcript variant 1, mRNA [NM_001034085] |
KLA | 1.26 |
1.17 |
1.14 |
1.13 |
1.12 |
1.11 |
.99 |
| ATP | .90 |
.90 |
.96 |
.98 |
1.59 |
1.71 |
1.16 |
| KLA/ATP | 1.23 |
1.16 |
.99 |
1.00 |
1.54 |
1.34 |
1.24 |
|
Ppp2r1b |  |
NM_028614 |
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform (Ppp2r1b), transcript variant 2, mRNA [NM_028614] |
KLA | 2.38 |
2.38 |
2.53 |
1.80 |
1.52 |
.95 |
1.16 |
| ATP | 1.17 |
1.29 |
1.04 |
1.09 |
1.16 |
1.19 |
1.00 |
| KLA/ATP | 2.59 |
2.78 |
1.82 |
2.31 |
1.34 |
1.03 |
.75 |
|
Ppp2r2a |  |
NM_028032 |
protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform (Ppp2r2a), mRNA [NM_028032] |
KLA | 2.18 |
2.42 |
2.58 |
2.17 |
2.08 |
1.83 |
1.57 |
| ATP | 1.06 |
1.12 |
.90 |
1.28 |
1.76 |
1.70 |
1.39 |
| KLA/ATP | 2.55 |
2.38 |
1.62 |
2.68 |
2.25 |
2.55 |
1.86 |
|
Ppp2r2b |  |
AK086561 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930037C08 product:unclassifiable, full insert sequence [AK086561] |
KLA | .94 |
1.02 |
1.07 |
1.02 |
1.02 |
.97 |
.98 |
| ATP | 1.01 |
1.04 |
1.01 |
.99 |
.97 |
.95 |
1.00 |
| KLA/ATP | 1.04 |
1.06 |
1.01 |
.96 |
1.02 |
.90 |
.93 |
|
Ppp2r2b |  |
NM_028392 |
protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform (Ppp2r2b), transcript variant 2, mRNA [NM_028392] |
KLA | 1.01 |
1.02 |
.96 |
1.00 |
1.04 |
1.01 |
1.00 |
| ATP | 1.00 |
.96 |
1.07 |
.93 |
.95 |
1.01 |
1.03 |
| KLA/ATP | .95 |
1.01 |
1.06 |
1.07 |
.98 |
1.02 |
1.03 |
|
Ppp2r2c |  |
NM_172994 |
protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform (Ppp2r2c), mRNA [NM_172994] |
KLA | .97 |
.98 |
.96 |
1.02 |
1.02 |
1.06 |
1.01 |
| ATP | .96 |
1.05 |
1.03 |
.98 |
1.01 |
1.04 |
1.06 |
| KLA/ATP | .98 |
.98 |
1.00 |
.96 |
1.00 |
.86 |
1.10 |
|
Ppp2r2d |  |
NM_026391 |
protein phosphatase 2, regulatory subunit B, delta isoform (Ppp2r2d), mRNA [NM_026391] |
KLA | 1.07 |
1.03 |
1.14 |
1.18 |
1.16 |
1.27 |
1.13 |
| ATP | .96 |
.93 |
.95 |
.76 |
1.34 |
2.21 |
1.22 |
| KLA/ATP | 1.01 |
1.01 |
1.01 |
.87 |
1.91 |
2.19 |
2.18 |
|
Ppp2r3a |  |
AK143212 |
0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130310B05 product:protein phosphatase 2 (formerly 2A), regulatory subunit B, alpha, full insert sequence [AK143212] |
KLA | 1.04 |
1.01 |
.92 |
1.16 |
1.08 |
1.09 |
1.04 |
| ATP | .98 |
.89 |
1.20 |
1.15 |
1.05 |
1.61 |
.79 |
| KLA/ATP | .95 |
.91 |
1.23 |
1.20 |
1.51 |
1.74 |
1.03 |
|
Ppp2r3c |  |
NM_021529 |
protein phosphatase 2, regulatory subunit B, gamma (Ppp2r3c), mRNA [NM_021529] |
KLA | 1.19 |
1.21 |
1.28 |
1.45 |
1.35 |
1.38 |
1.59 |
| ATP | 1.02 |
.93 |
1.14 |
.95 |
.98 |
1.12 |
1.39 |
| KLA/ATP | 1.23 |
1.23 |
1.48 |
1.08 |
1.14 |
1.12 |
2.02 |
|
Ppp2r5a |  |
NM_144880 |
protein phosphatase 2, regulatory subunit B (B56), alpha isoform (Ppp2r5a), mRNA [NM_144880] |
KLA | 3.55 |
3.70 |
4.28 |
3.81 |
3.87 |
2.52 |
1.55 |
| ATP | .99 |
1.00 |
.80 |
.82 |
1.04 |
1.62 |
1.41 |
| KLA/ATP | 3.48 |
3.79 |
2.82 |
2.77 |
2.16 |
2.02 |
2.43 |
|
Ppp2r5b |  |
NM_198168 |
protein phosphatase 2, regulatory subunit B (B56), beta isoform (Ppp2r5b), mRNA [NM_198168] |
KLA | 1.12 |
1.20 |
1.13 |
1.18 |
1.13 |
.98 |
1.12 |
| ATP | .95 |
.98 |
.92 |
.98 |
.84 |
1.03 |
1.48 |
| KLA/ATP | 1.16 |
1.13 |
.88 |
.91 |
1.00 |
1.00 |
1.38 |
|
Ppp2r5c |  |
NM_012023 |
protein phosphatase 2, regulatory subunit B (B56), gamma isoform (Ppp2r5c), transcript variant 1, mRNA [NM_012023] |
KLA | .80 |
.82 |
.82 |
.78 |
.88 |
1.07 |
1.27 |
| ATP | 1.07 |
1.11 |
1.09 |
1.14 |
.89 |
.64 |
1.07 |
| KLA/ATP | .87 |
.84 |
.77 |
.82 |
.73 |
.76 |
1.09 |
|
Ppp2r5d |  |
NM_009358 |
protein phosphatase 2, regulatory subunit B (B56), delta isoform (Ppp2r5d), mRNA [NM_009358] |
KLA | .87 |
.86 |
.80 |
.75 |
.74 |
.77 |
.69 |
| ATP | .97 |
.96 |
1.05 |
1.10 |
1.00 |
.88 |
.62 |
| KLA/ATP | .91 |
.89 |
.84 |
.77 |
.79 |
.69 |
.59 |
|
Ppp2r5e |  |
NM_012024 |
protein phosphatase 2, regulatory subunit B (B56), epsilon isoform (Ppp2r5e), mRNA [NM_012024] |
KLA | 1.07 |
1.09 |
1.12 |
1.14 |
1.11 |
1.11 |
1.15 |
| ATP | .99 |
.85 |
.92 |
.74 |
.76 |
1.23 |
1.30 |
| KLA/ATP | .99 |
.98 |
1.05 |
.77 |
.87 |
1.22 |
1.64 |
|
Prkaa1 |  |
NM_001013367 |
protein kinase, AMP-activated, alpha 1 catalytic subunit (Prkaa1), mRNA [NM_001013367] |
KLA | 1.10 |
1.03 |
1.17 |
1.25 |
1.24 |
1.61 |
2.29 |
| ATP | 1.04 |
1.07 |
1.10 |
1.08 |
1.04 |
2.01 |
2.13 |
| KLA/ATP | 1.07 |
1.04 |
1.04 |
1.17 |
.95 |
1.90 |
3.90 |
|
Prkaa2 |  |
NM_178143 |
protein kinase, AMP-activated, alpha 2 catalytic subunit (Prkaa2), mRNA [NM_178143] |
KLA | .93 |
.94 |
.94 |
.90 |
.92 |
.92 |
.99 |
| ATP | 1.00 |
1.14 |
.93 |
1.01 |
1.00 |
1.11 |
.98 |
| KLA/ATP | 1.00 |
.97 |
.99 |
1.01 |
.98 |
1.02 |
.98 |
|
Prkca |  |
NM_011101 |
protein kinase C, alpha (Prkca), mRNA [NM_011101] |
KLA | 1.00 |
.96 |
.94 |
.95 |
.95 |
.89 |
.96 |
| ATP | 1.00 |
1.03 |
.91 |
.94 |
.82 |
.87 |
1.13 |
| KLA/ATP | 1.02 |
.95 |
.91 |
.86 |
.78 |
.84 |
.94 |
|
Prkcz |  |
NM_008860 |
protein kinase C, zeta (Prkcz), transcript variant 1, mRNA [NM_008860] |
KLA | .92 |
.90 |
1.00 |
.99 |
1.07 |
1.05 |
1.12 |
| ATP | 1.01 |
.95 |
.94 |
.93 |
1.04 |
1.04 |
.95 |
| KLA/ATP | .95 |
.94 |
.95 |
.94 |
.99 |
1.02 |
.98 |
|
Prl |  |
NM_011164 |
prolactin (Prl), mRNA [NM_011164] |
KLA | 1.01 |
1.00 |
1.06 |
1.02 |
1.05 |
.96 |
.97 |
| ATP | .99 |
1.02 |
.97 |
.98 |
.97 |
.95 |
1.00 |
| KLA/ATP | 1.00 |
1.01 |
1.00 |
.97 |
.96 |
.87 |
.95 |
|
Prlr |  |
AK083198 |
adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630026G18 product:unclassifiable, full insert sequence [AK083198] |
KLA | .99 |
1.07 |
1.00 |
.95 |
1.01 |
.90 |
1.01 |
| ATP | 1.02 |
.94 |
.97 |
1.00 |
.97 |
.94 |
.96 |
| KLA/ATP | .98 |
.94 |
.96 |
.96 |
.99 |
1.07 |
1.02 |
|
Prlr |  |
AK087727 |
2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330012C04 product:hypothetical protein, full insert sequence [AK087727] |
KLA | 1.03 |
1.00 |
.99 |
1.01 |
1.02 |
1.04 |
.99 |
| ATP | 1.00 |
.95 |
1.13 |
1.06 |
.97 |
.98 |
1.04 |
| KLA/ATP | .97 |
1.01 |
.88 |
1.02 |
1.01 |
1.03 |
1.05 |
|
Prlr |  |
NM_011169 |
prolactin receptor (Prlr), mRNA [NM_011169] |
KLA | .93 |
1.03 |
1.12 |
1.06 |
1.05 |
1.14 |
1.15 |
| ATP | .95 |
.99 |
1.11 |
1.13 |
1.06 |
1.19 |
1.18 |
| KLA/ATP | 1.02 |
1.01 |
1.05 |
1.10 |
1.10 |
1.21 |
1.07 |
|
Pten |  |
NM_008960 |
phosphatase and tensin homolog (Pten), mRNA [NM_008960] |
KLA | .79 |
.73 |
.61 |
.59 |
.56 |
.70 |
1.00 |
| ATP | 1.04 |
1.11 |
1.07 |
1.12 |
1.03 |
1.38 |
.83 |
| KLA/ATP | .75 |
.69 |
.60 |
.74 |
.93 |
1.09 |
1.24 |
|
Ptk2 |  |
NM_007982 |
PTK2 protein tyrosine kinase 2 (Ptk2), mRNA [NM_007982] |
KLA | .99 |
.99 |
1.02 |
1.04 |
1.09 |
1.22 |
1.57 |
| ATP | 1.04 |
1.09 |
.95 |
.98 |
.67 |
.96 |
.87 |
| KLA/ATP | .99 |
1.03 |
.87 |
.93 |
.81 |
1.16 |
1.04 |
|
Rac1 |  |
NM_009007 |
RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] |
KLA | 1.02 |
1.01 |
1.02 |
.99 |
1.03 |
1.15 |
1.08 |
| ATP | .99 |
1.15 |
1.01 |
1.27 |
1.06 |
1.20 |
1.06 |
| KLA/ATP | 1.00 |
1.04 |
.88 |
1.16 |
.91 |
1.21 |
1.38 |
|
Raf1 |  |
AK036317 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] |
KLA | 1.47 |
1.34 |
1.55 |
1.29 |
1.59 |
1.32 |
1.46 |
| ATP | 1.05 |
.98 |
.54 |
.63 |
3.32 |
2.07 |
1.01 |
| KLA/ATP | 1.57 |
1.33 |
.79 |
.96 |
2.26 |
1.38 |
1.35 |
|
Raf1 |  |
NM_029780 |
v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] |
KLA | 1.65 |
1.64 |
1.93 |
1.77 |
1.77 |
1.72 |
1.81 |
| ATP | .95 |
.96 |
.83 |
.80 |
2.22 |
2.92 |
1.19 |
| KLA/ATP | 1.68 |
1.64 |
1.39 |
1.32 |
1.85 |
2.50 |
2.06 |
|
Rbl2 |  |
NM_011250 |
retinoblastoma-like 2 (Rbl2), mRNA [NM_011250] |
KLA | .66 |
.69 |
.65 |
.51 |
.55 |
.57 |
.78 |
| ATP | 1.11 |
1.32 |
.95 |
1.14 |
.57 |
.47 |
.65 |
| KLA/ATP | .77 |
.76 |
.52 |
.64 |
.41 |
.52 |
.59 |
|
Rela |  |
NM_009045 |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] |
KLA | 2.05 |
2.05 |
2.07 |
1.75 |
1.83 |
1.58 |
1.33 |
| ATP | 1.03 |
1.08 |
1.10 |
1.44 |
1.61 |
2.48 |
1.05 |
| KLA/ATP | 2.17 |
2.27 |
2.05 |
2.47 |
1.93 |
2.35 |
2.02 |
|
Reln |  |
NM_011261 |
reelin (Reln), mRNA [NM_011261] |
KLA | 1.00 |
1.00 |
.98 |
1.03 |
1.00 |
.99 |
.99 |
| ATP | 1.00 |
.99 |
1.05 |
1.08 |
1.01 |
.99 |
1.00 |
| KLA/ATP | 1.01 |
1.02 |
1.05 |
1.03 |
.98 |
.98 |
.98 |
|
Rheb |  |
NM_053075 |
RAS-homolog enriched in brain (Rheb), mRNA [NM_053075] |
KLA | 1.03 |
1.00 |
.99 |
.99 |
.95 |
1.03 |
1.09 |
| ATP | .99 |
.89 |
.95 |
.81 |
1.07 |
1.19 |
.90 |
| KLA/ATP | 1.01 |
.87 |
.97 |
.82 |
1.06 |
1.22 |
.88 |
|
Rps6 |  |
AK013825 |
adult male hippocampus cDNA, RIKEN full-length enriched library, clone:2900086I01 product:ribosomal protein S6, full insert sequence. [AK013825] |
KLA | 1.04 |
1.06 |
1.03 |
.99 |
.94 |
.96 |
1.26 |
| ATP | 1.01 |
1.00 |
1.04 |
.99 |
.99 |
.94 |
1.12 |
| KLA/ATP | 1.02 |
1.08 |
.95 |
1.04 |
.94 |
.97 |
.90 |
|
Rps6 |  |
NM_009096 |
ribosomal protein S6 (Rps6), mRNA [NM_009096] |
KLA | 1.01 |
1.01 |
.94 |
.87 |
.89 |
.66 |
.72 |
| ATP | 1.11 |
1.07 |
1.10 |
1.12 |
1.12 |
1.03 |
.47 |
| KLA/ATP | .96 |
1.04 |
1.22 |
1.10 |
.86 |
.84 |
.40 |
|
Rps6kb1 |  |
NM_001114334 |
ribosomal protein S6 kinase, polypeptide 1 (Rps6kb1), transcript variant 1, mRNA [NM_001114334] |
KLA | .99 |
1.00 |
.90 |
.89 |
.99 |
.99 |
.92 |
| ATP | 1.01 |
.96 |
1.00 |
.79 |
1.36 |
1.19 |
.72 |
| KLA/ATP | 1.08 |
.99 |
.93 |
.92 |
1.18 |
.90 |
.56 |
|
Rps6kb1 |  |
NM_028259 |
ribosomal protein S6 kinase, polypeptide 1 (Rps6kb1), transcript variant 2, mRNA [NM_028259] |
KLA | 1.01 |
.93 |
1.07 |
1.04 |
.99 |
.99 |
.98 |
| ATP | 1.09 |
1.05 |
1.00 |
1.01 |
1.08 |
1.03 |
1.03 |
| KLA/ATP | 1.07 |
1.04 |
.94 |
.98 |
1.03 |
1.05 |
1.05 |
|
Rps6kb2 |  |
AK090093 |
kidney CCL-142 RAG cDNA, RIKEN full-length enriched library, clone:G430107K15 product:ribosomal protein S6 kinase, 70kD, polypeptide 2, full insert sequence [AK090093] |
KLA | .97 |
1.01 |
.98 |
.97 |
.98 |
1.04 |
1.07 |
| ATP | 1.00 |
1.08 |
1.06 |
1.09 |
1.11 |
1.06 |
1.03 |
| KLA/ATP | 1.05 |
.96 |
.86 |
1.03 |
1.40 |
1.07 |
.99 |
|
Rps6kb2 |  |
NM_021485 |
ribosomal protein S6 kinase, polypeptide 2 (Rps6kb2), mRNA [NM_021485] |
KLA | 1.36 |
1.40 |
1.45 |
1.40 |
1.63 |
1.57 |
1.46 |
| ATP | 1.08 |
1.19 |
.97 |
1.15 |
.90 |
.99 |
1.34 |
| KLA/ATP | 1.44 |
1.55 |
1.09 |
1.39 |
1.00 |
1.12 |
1.77 |
|
Rxra |  |
NM_011305 |
retinoid X receptor alpha (Rxra), mRNA [NM_011305] |
KLA | .53 |
.55 |
.50 |
.52 |
.54 |
.85 |
1.09 |
| ATP | .95 |
1.00 |
1.18 |
1.00 |
.82 |
1.20 |
1.65 |
| KLA/ATP | .57 |
.55 |
.58 |
.55 |
.67 |
1.07 |
1.57 |
|
Sgk1 |  |
AK043284 |
7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730081A20 product:unclassifiable, full insert sequence. [AK043284] |
KLA | .94 |
1.04 |
1.04 |
1.00 |
.97 |
.96 |
1.03 |
| ATP | 1.08 |
.99 |
1.01 |
.96 |
1.00 |
.93 |
1.00 |
| KLA/ATP | .95 |
.95 |
1.02 |
.96 |
.97 |
1.00 |
.94 |
|
Sgk1 |  |
NM_011361 |
serum/glucocorticoid regulated kinase 1 (Sgk1), mRNA [NM_011361] |
KLA | 1.34 |
1.00 |
1.31 |
.82 |
1.31 |
2.97 |
2.62 |
| ATP | 1.05 |
1.05 |
3.10 |
12.21 |
20.68 |
7.13 |
1.80 |
| KLA/ATP | 1.31 |
1.17 |
2.98 |
10.32 |
15.03 |
6.81 |
4.65 |
|
Sgk2 |  |
NM_013731 |
serum/glucocorticoid regulated kinase 2 (Sgk2), mRNA [NM_013731] |
KLA | .98 |
1.05 |
.92 |
.98 |
.90 |
1.02 |
.97 |
| ATP | .99 |
.99 |
.98 |
.99 |
1.07 |
1.01 |
1.04 |
| KLA/ATP | .97 |
.96 |
.99 |
.95 |
1.10 |
1.00 |
1.03 |
|
Sgk3 |  |
AK077817 |
adult male thymus cDNA, RIKEN full-length enriched library, clone:5832447I09 product:unclassifiable, full insert sequence. [AK077817] |
KLA | 3.06 |
2.46 |
2.50 |
1.73 |
1.76 |
1.50 |
1.25 |
| ATP | 1.01 |
1.13 |
.96 |
.63 |
.81 |
.90 |
1.02 |
| KLA/ATP | 3.57 |
2.95 |
2.27 |
.95 |
1.08 |
.97 |
1.33 |
|
Sgk3 |  |
AK083319 |
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:C920004G11 product:similar to PROTEIN KINASE (DJ138B7.2) (SERUM/GLUCOCORTICOID REGULATED KINASE 2) (SIMILAR TO SERUM/GLUCOCORTICOID REGULATED KINASE 2) [Hom |
KLA | 1.00 |
1.02 |
1.01 |
1.05 |
.99 |
1.01 |
1.07 |
| ATP | 1.02 |
1.08 |
1.10 |
.97 |
.98 |
.96 |
.99 |
| KLA/ATP | 1.11 |
1.05 |
1.02 |
1.10 |
1.05 |
.96 |
.97 |
|
Sgk3 |  |
NM_133220 |
serum/glucocorticoid regulated kinase 3 (Sgk3), transcript variant 1, mRNA [NM_133220] |
KLA | 4.27 |
3.85 |
4.76 |
3.94 |
3.80 |
2.09 |
1.17 |
| ATP | 1.20 |
1.51 |
1.00 |
1.14 |
.61 |
.62 |
1.06 |
| KLA/ATP | 3.44 |
4.17 |
2.96 |
3.56 |
1.43 |
.84 |
1.36 |
|
Sos1 |  |
NM_009231 |
Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] |
KLA | 2.36 |
2.40 |
3.42 |
3.15 |
2.78 |
1.81 |
1.71 |
| ATP | .99 |
1.00 |
.99 |
1.15 |
1.14 |
1.25 |
1.24 |
| KLA/ATP | 2.41 |
2.26 |
1.95 |
2.44 |
1.47 |
1.66 |
1.37 |
|
Sos2 |  |
XM_127051 |
gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] |
KLA | .81 |
.77 |
.79 |
.92 |
1.04 |
1.06 |
1.20 |
| ATP | 1.00 |
1.00 |
1.09 |
.79 |
.68 |
.81 |
.94 |
| KLA/ATP | .77 |
.69 |
.71 |
.60 |
.64 |
.77 |
1.07 |
|
Spp1 |  |
NM_009263 |
secreted phosphoprotein 1 (Spp1), mRNA [NM_009263] |
KLA | 1.41 |
1.62 |
1.39 |
1.31 |
1.31 |
1.00 |
.51 |
| ATP | 1.08 |
1.21 |
1.49 |
1.79 |
2.55 |
3.51 |
3.41 |
| KLA/ATP | 1.40 |
1.54 |
1.51 |
1.43 |
2.01 |
3.18 |
2.46 |
|
Syk |  |
NM_011518 |
spleen tyrosine kinase (Syk), mRNA [NM_011518] |
KLA | 2.48 |
2.59 |
2.57 |
2.26 |
3.29 |
3.75 |
3.19 |
| ATP | .96 |
.85 |
.59 |
1.01 |
2.80 |
3.77 |
2.11 |
| KLA/ATP | 2.56 |
2.09 |
1.16 |
1.35 |
2.50 |
4.33 |
5.10 |
|
Tcl1 |  |
NM_009337 |
T-cell lymphoma breakpoint 1 (Tcl1), mRNA [NM_009337] |
KLA | 1.04 |
1.05 |
1.03 |
1.02 |
1.09 |
1.07 |
1.03 |
| ATP | .96 |
1.00 |
1.10 |
1.21 |
1.14 |
1.20 |
1.06 |
| KLA/ATP | 1.00 |
1.04 |
1.07 |
1.48 |
1.32 |
1.29 |
1.10 |
|
Tcl1b1 |  |
NM_013773 |
T-cell leukemia/lymphoma 1B, 1 (Tcl1b1), mRNA [NM_013773] |
KLA | .86 |
1.03 |
1.06 |
1.08 |
.98 |
1.02 |
1.13 |
| ATP | 1.01 |
.98 |
1.00 |
1.04 |
1.03 |
1.04 |
1.01 |
| KLA/ATP | 1.07 |
1.06 |
1.02 |
1.08 |
1.08 |
1.14 |
1.02 |
|
Tcl1b4 |  |
NM_013774 |
T-cell leukemia/lymphoma 1B, 4 (Tcl1b4), mRNA [NM_013774] |
KLA | 1.16 |
1.10 |
1.19 |
1.10 |
1.15 |
1.21 |
1.13 |
| ATP | 1.02 |
.99 |
.98 |
.95 |
1.00 |
1.16 |
1.08 |
| KLA/ATP | 1.02 |
1.07 |
1.10 |
1.05 |
1.11 |
1.19 |
1.17 |
|
Tek |  |
AK053336 |
0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130010K24 product:endothelial-specific receptor tyrosine kinase, full insert sequence. [AK053336] |
KLA | .93 |
.98 |
.93 |
.90 |
.96 |
1.01 |
1.10 |
| ATP | 1.01 |
.97 |
.93 |
.99 |
.91 |
.98 |
.99 |
| KLA/ATP | 1.02 |
1.06 |
.95 |
.93 |
.92 |
.91 |
.92 |
|
Tek |  |
NM_013690 |
endothelial-specific receptor tyrosine kinase (Tek), mRNA [NM_013690] |
KLA | 1.00 |
.95 |
1.02 |
.93 |
.98 |
.97 |
1.06 |
| ATP | 1.05 |
1.07 |
1.01 |
1.05 |
.98 |
1.08 |
1.13 |
| KLA/ATP | .94 |
.96 |
1.03 |
1.11 |
1.15 |
.99 |
1.25 |
|
Thbs1 |  |
NM_011580 |
thrombospondin 1 (Thbs1), mRNA [NM_011580] |
KLA | 2.22 |
2.22 |
2.74 |
3.10 |
4.57 |
7.17 |
7.22 |
| ATP | 1.16 |
2.53 |
8.45 |
12.26 |
15.50 |
43.06 |
35.83 |
| KLA/ATP | 2.46 |
3.43 |
8.29 |
17.50 |
28.16 |
46.17 |
54.67 |
|
Thbs2 |  |
NM_011581 |
thrombospondin 2 (Thbs2), mRNA [NM_011581] |
KLA | .99 |
1.03 |
1.04 |
1.03 |
1.04 |
1.17 |
1.03 |
| ATP | 1.01 |
1.04 |
1.01 |
1.02 |
.98 |
1.03 |
.97 |
| KLA/ATP | 1.08 |
1.04 |
.95 |
1.05 |
1.15 |
1.14 |
1.04 |
|
Thbs3 |  |
NM_013691 |
thrombospondin 3 (Thbs3), mRNA [NM_013691] |
KLA | .86 |
.93 |
.86 |
.95 |
.90 |
.79 |
.79 |
| ATP | 1.06 |
1.02 |
1.11 |
1.10 |
.96 |
1.03 |
1.07 |
| KLA/ATP | .90 |
.88 |
.92 |
.92 |
.98 |
.96 |
.98 |
|
Thbs4 |  |
NM_011582 |
thrombospondin 4 (Thbs4), mRNA [NM_011582] |
KLA | 1.16 |
1.13 |
1.19 |
1.13 |
1.13 |
1.16 |
1.07 |
| ATP | 1.00 |
1.14 |
1.07 |
.99 |
1.07 |
1.25 |
1.10 |
| KLA/ATP | 1.16 |
1.18 |
1.24 |
1.55 |
1.55 |
1.94 |
1.48 |
|
Them4 |  |
AK014834 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4921507I02 product:weakly similar to C-TERMINAL MODULATOR PROTEIN [Homo sapiens], full insert sequence [AK014834] |
KLA | .89 |
.99 |
1.02 |
.94 |
.87 |
1.01 |
1.07 |
| ATP | .99 |
.98 |
.89 |
.95 |
.96 |
.91 |
.96 |
| KLA/ATP | .94 |
.99 |
1.00 |
.88 |
.94 |
.94 |
.94 |
|
Them4 |  |
NM_029431 |
thioesterase superfamily member 4 (Them4), mRNA [NM_029431] |
KLA | 1.07 |
1.10 |
1.13 |
1.32 |
1.28 |
1.43 |
1.56 |
| ATP | .93 |
.91 |
1.20 |
1.09 |
.84 |
1.36 |
1.34 |
| KLA/ATP | 1.00 |
1.07 |
1.20 |
1.14 |
1.00 |
1.42 |
1.11 |
|
Tlr2 |  |
NM_011905 |
toll-like receptor 2 (Tlr2), mRNA [NM_011905] |
KLA | 13.65 |
11.82 |
8.87 |
7.95 |
4.67 |
2.78 |
2.33 |
| ATP | 1.06 |
1.24 |
2.76 |
6.28 |
11.55 |
13.82 |
.67 |
| KLA/ATP | 13.11 |
12.91 |
14.48 |
13.84 |
14.18 |
11.14 |
2.78 |
|
Tlr4 |  |
NM_021297 |
toll-like receptor 4 (Tlr4), mRNA [NM_021297] |
KLA | .69 |
.61 |
.75 |
.94 |
.64 |
.81 |
.73 |
| ATP | .95 |
.90 |
1.12 |
.56 |
.47 |
1.51 |
1.53 |
| KLA/ATP | .57 |
.62 |
1.01 |
.64 |
.39 |
.73 |
1.13 |
|
Tnc |  |
AK048765 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230053B09 product:tenascin C, full insert sequence. [AK048765] |
KLA | 1.22 |
1.24 |
1.38 |
1.04 |
.98 |
1.03 |
1.03 |
| ATP | 1.01 |
1.04 |
1.02 |
1.08 |
.99 |
1.04 |
1.04 |
| KLA/ATP | 1.28 |
1.36 |
1.19 |
1.05 |
1.03 |
1.06 |
1.04 |
|
Tnc |  |
NM_011607 |
tenascin C (Tnc), mRNA [NM_011607] |
KLA | 1.41 |
1.56 |
1.78 |
1.51 |
1.60 |
1.33 |
1.01 |
| ATP | 1.05 |
1.05 |
1.05 |
1.18 |
1.03 |
1.24 |
1.11 |
| KLA/ATP | 1.46 |
1.74 |
1.63 |
1.64 |
1.29 |
1.26 |
1.12 |
|
Tnn |  |
NM_177839 |
tenascin N (Tnn), mRNA [NM_177839] |
KLA | 1.62 |
1.81 |
1.88 |
1.81 |
1.51 |
1.28 |
1.02 |
| ATP | 1.00 |
1.12 |
1.10 |
1.04 |
1.05 |
1.18 |
1.02 |
| KLA/ATP | 1.79 |
1.82 |
1.73 |
1.57 |
1.32 |
1.13 |
1.12 |
|
Tnr |  |
NM_022312 |
tenascin R (Tnr), mRNA [NM_022312] |
KLA | .98 |
.94 |
1.01 |
1.02 |
.96 |
.98 |
.94 |
| ATP | 1.08 |
.97 |
1.00 |
.95 |
1.01 |
.89 |
1.10 |
| KLA/ATP | .98 |
1.03 |
1.00 |
.97 |
.94 |
.91 |
1.03 |
|
Tnxb |  |
NM_031176 |
tenascin XB (Tnxb), mRNA [NM_031176] |
KLA | 1.02 |
.95 |
1.00 |
.96 |
.97 |
.99 |
.98 |
| ATP | .99 |
1.02 |
1.00 |
1.02 |
1.00 |
.98 |
1.01 |
| KLA/ATP | .99 |
1.04 |
1.01 |
.95 |
.99 |
.95 |
.97 |
|
Trp53 |  |
NM_011640 |
transformation related protein 53 (Trp53), mRNA [NM_011640] |
KLA | 1.25 |
1.37 |
1.11 |
.86 |
.72 |
.71 |
.95 |
| ATP | 1.15 |
1.32 |
.90 |
1.85 |
1.26 |
.68 |
.70 |
| KLA/ATP | 1.66 |
1.49 |
.80 |
1.76 |
.81 |
.65 |
.74 |
|
Tsc1 |  |
AK083363 |
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:C920023H23 product:tuberous sclerosis 1, full insert sequence. [AK083363] |
KLA | .69 |
.66 |
.60 |
.71 |
.85 |
.78 |
.77 |
| ATP | 1.13 |
1.26 |
1.70 |
2.23 |
1.77 |
.87 |
.90 |
| KLA/ATP | .76 |
.77 |
.90 |
1.19 |
1.74 |
.80 |
.72 |
|
Tsc1 |  |
NM_022887 |
tuberous sclerosis 1 (Tsc1), mRNA [NM_022887] |
KLA | .93 |
.94 |
1.00 |
1.04 |
1.01 |
.95 |
1.10 |
| ATP | 1.12 |
1.10 |
1.12 |
1.27 |
1.66 |
1.45 |
1.80 |
| KLA/ATP | .95 |
1.00 |
1.06 |
1.03 |
1.26 |
1.30 |
1.74 |
|
Tsc2 |  |
NM_011647 |
tuberous sclerosis 2 (Tsc2), transcript variant 1, mRNA [NM_011647] |
KLA | .91 |
.88 |
.87 |
.83 |
.83 |
.88 |
.99 |
| ATP | .91 |
.91 |
1.04 |
.88 |
.76 |
.68 |
.91 |
| KLA/ATP | .88 |
.89 |
.88 |
.76 |
.65 |
.67 |
.85 |
|
Vegfa |  |
NM_001025250 |
vascular endothelial growth factor A (Vegfa), transcript variant 1, mRNA [NM_001025250] |
KLA | .49 |
.48 |
.46 |
.46 |
.39 |
.64 |
1.18 |
| ATP | 1.05 |
1.37 |
3.82 |
10.55 |
12.51 |
24.20 |
7.85 |
| KLA/ATP | .48 |
.59 |
1.45 |
7.42 |
19.75 |
27.42 |
22.35 |
|
Vegfa |  |
NM_001025257 |
vascular endothelial growth factor A (Vegfa), transcript variant 3, mRNA [NM_001025257] |
KLA | .72 |
.71 |
.66 |
.70 |
.65 |
.80 |
1.22 |
| ATP | 1.01 |
1.21 |
3.24 |
11.12 |
11.09 |
18.59 |
5.43 |
| KLA/ATP | .68 |
.71 |
1.47 |
5.94 |
15.06 |
20.32 |
17.31 |
|
Vegfb |  |
NM_011697 |
vascular endothelial growth factor B (Vegfb), mRNA [NM_011697] |
KLA | .65 |
.63 |
.65 |
.63 |
.52 |
.38 |
.37 |
| ATP | 1.11 |
1.07 |
1.16 |
1.44 |
1.72 |
1.22 |
.43 |
| KLA/ATP | .67 |
.67 |
.89 |
.90 |
1.19 |
.86 |
.31 |
|
Vegfc |  |
NM_009506 |
vascular endothelial growth factor C (Vegfc), mRNA [NM_009506] |
KLA | 2.07 |
2.21 |
2.04 |
3.27 |
2.51 |
1.73 |
2.90 |
| ATP | 1.08 |
1.03 |
1.24 |
1.32 |
2.55 |
5.18 |
2.58 |
| KLA/ATP | 2.20 |
2.29 |
2.72 |
2.97 |
4.35 |
4.24 |
5.06 |
|
Vtn |  |
NM_011707 |
vitronectin (Vtn), mRNA [NM_011707] |
KLA | 1.05 |
1.05 |
1.01 |
1.00 |
.97 |
1.04 |
.95 |
| ATP | .94 |
.99 |
1.00 |
.94 |
.96 |
1.04 |
1.09 |
| KLA/ATP | .97 |
1.00 |
1.02 |
.99 |
.98 |
.94 |
.98 |
|
Vwf |  |
AK044921 |
9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130011O06 product:VON WILLEBRAND FACTOR (FRAGMENT) homolog [Saguinus bicolor], full insert sequence. [AK044921] |
KLA | 1.02 |
.96 |
.97 |
.95 |
.97 |
1.00 |
.91 |
| ATP | 1.01 |
1.03 |
.93 |
1.02 |
1.01 |
1.00 |
1.08 |
| KLA/ATP | .99 |
.93 |
.99 |
.96 |
1.02 |
1.01 |
1.08 |
|
Vwf |  |
NM_011708 |
Von Willebrand factor homolog (Vwf), mRNA [NM_011708] |
KLA | .56 |
.56 |
.51 |
.41 |
.37 |
.50 |
.33 |
| ATP | 1.09 |
.99 |
.77 |
.88 |
3.26 |
2.28 |
.64 |
| KLA/ATP | .65 |
.58 |
.46 |
.52 |
2.61 |
3.48 |
1.38 |
|
Ywhab |  |
NM_018753 |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide (Ywhab), mRNA [NM_018753] |
KLA | 1.03 |
1.15 |
1.18 |
1.10 |
1.20 |
1.20 |
1.23 |
| ATP | 1.02 |
1.08 |
.84 |
1.06 |
1.08 |
1.24 |
1.24 |
| KLA/ATP | 1.15 |
1.18 |
.82 |
1.17 |
.91 |
1.24 |
1.58 |
|
Ywhae |  |
NM_009536 |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide (Ywhae), mRNA [NM_009536] |
KLA | 1.32 |
1.35 |
1.43 |
1.40 |
1.46 |
1.45 |
1.19 |
| ATP | 1.09 |
1.30 |
1.21 |
1.51 |
1.16 |
.97 |
1.01 |
| KLA/ATP | 1.45 |
1.50 |
1.33 |
1.85 |
1.25 |
1.16 |
1.08 |
|
Ywhag |  |
NM_018871 |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide (Ywhag), mRNA [NM_018871] |
KLA | .87 |
.96 |
.92 |
.89 |
1.14 |
1.30 |
1.77 |
| ATP | 1.08 |
1.22 |
.86 |
.83 |
.91 |
1.46 |
1.09 |
| KLA/ATP | 1.05 |
1.04 |
.61 |
.72 |
.76 |
1.44 |
1.52 |
|
Ywhah |  |
NM_011738 |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide (Ywhah), mRNA [NM_011738] |
KLA | .55 |
.54 |
.49 |
.44 |
.38 |
.58 |
.70 |
| ATP | .99 |
.93 |
1.14 |
.81 |
.62 |
.53 |
1.07 |
| KLA/ATP | .54 |
.52 |
.54 |
.35 |
.37 |
.35 |
.68 |
|
Ywhaq |  |
AK037746 |
16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130046D12 product:unclassifiable, full insert sequence [AK037746] |
KLA | .97 |
.93 |
.94 |
.95 |
.97 |
.96 |
.95 |
| ATP | 1.09 |
1.07 |
1.44 |
1.49 |
1.04 |
1.01 |
.96 |
| KLA/ATP | 1.04 |
.96 |
1.11 |
1.36 |
1.01 |
1.03 |
.87 |
|
Ywhaq |  |
NM_011739 |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide (Ywhaq), mRNA [NM_011739] |
KLA | .93 |
.98 |
.96 |
.99 |
.92 |
.76 |
.88 |
| ATP | 1.07 |
1.08 |
1.01 |
1.35 |
1.37 |
1.28 |
.70 |
| KLA/ATP | .97 |
1.04 |
.94 |
1.17 |
1.09 |
1.18 |
.77 |
|
Ywhaz |  |
AK050511 |
adult pancreas islet cells cDNA, RIKEN full-length enriched library, clone:C820005J08 product:tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide, full insert sequence. [AK050511] |
KLA | .99 |
.96 |
.97 |
.96 |
1.00 |
.95 |
.96 |
| ATP | .99 |
1.00 |
.98 |
1.01 |
1.04 |
.94 |
1.01 |
| KLA/ATP | .99 |
.97 |
1.00 |
.98 |
.88 |
.97 |
1.01 |
|
Ywhaz |  |
NM_011740 |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide (Ywhaz), mRNA [NM_011740] |
KLA | 1.79 |
1.86 |
1.98 |
2.10 |
2.11 |
2.10 |
1.30 |
| ATP | 1.00 |
1.21 |
.95 |
1.37 |
1.21 |
1.42 |
1.08 |
| KLA/ATP | 1.73 |
1.92 |
1.58 |
2.28 |
1.68 |
1.76 |
1.47 |
|